

Name: Thomas A. Hope, MD

Position: Professor in Residence, Step 1
Department of Radiology and Biomedical Imaging
School of Medicine

Address: Room M372, Box 0628
University of California, San Francisco
San Francisco, CA 94143
Voice: (415) 353-8937
email: thomas.hope@ucsf.edu

EDUCATION/TRAINING

1997 – 2001	Duke University, Durham, NC	B.A. in Economics, B.S. in Biology
2003 – 2007	Stanford University School of Medicine	M.D.
2007 – 2008	Kaiser San Francisco, San Francisco, CA	Intern, Internal Medicine
2008 – 2012	University of California, San Francisco, CA	Resident, Diagnostic Radiology
2012 – 2013	Stanford Medical Center, Stanford, CA	Clinical Fellow, Body MRI and Nuclear Medicine

LICENSES, CERTIFICATION:

2009	Medical Licensure, California, A107695
2012	American Board of Radiology, Certificate in Diagnostic Radiology, 61282
2012	Drug Enforcement Administration (DEA), registration number FH2871867
2013	Radiology Supervisor and Operator Certificate, RHL00171995
2013	American Board of Nuclear Medicine, 08651

PRINCIPLE POSITIONS HELD:

2022 – present	University of California, San Francisco	Professor in Residence, Radiology and Biomedical Imaging
2022 – present	University of California, San Francisco	Vice Chair of Clinical Operations and Strategy
2020 – 2022	University of California, San Francisco	Associate Chair for Business Strategy
2019 – present	University of California, San Francisco	Director for Molecular Therapy
2018 – 2022	University of California, San Francisco	Associate Professor in Residence, Radiology and Biomedical Imaging
2018 – present	San Francisco VA Medical Center	Chief of Nuclear Medicine
2016 – present	University of California, San Francisco	Co-director, Neuroendocrine Tumor Destination Program
2015 – 2019	University of California, San Francisco	Co-director PET/MRI
2012 – 2018	University of California, San Francisco	Assistant Professor in Residence, Radiology and Biomedical Imaging
2013 – present	San Francisco VA Medical Center	Staff Radiologist
2001 – 2003	Fletcher Spaght, Boston, MA	Research Analyst

HONORS/AWARDS:

2001	Summa Cum Laude, Duke University.
2001	Phi Beta Kappa, Duke University.
2006	Trainee Research Prize, RSNA.

2007 W. S. Moore Award, Nominee, ISMRM.
 2011 Magnum Cum Laude Merit Award, ISMRM.
 2012 Roentgen Resident/Fellow Research Award, RSNA.
 2012 Alexander Margulis Society, Excellence in Research Award, UCSF.
 2014 Wylie J. Dodds Research Award, SAR.
 2015 Best Oral Presentation, Second Place, Third Theranostics World Congress on Ga-68.
 2015 Certificate of Merit, RSNA.
 2016 Henkin Fellowship, SNMMI.
 2016 Outstanding Teacher Award, ISMRM.
 2016 Marc Tetalman Memorial Award, SNMMI.
 2017 Paper of the Year, Abdominal Radiology.
 2017 Best GU abstract presentation, Society of Abdominal Radiology.
 2017 Outstanding Teacher Award, ISMRM.
 2017 Young Investigator Award, Prostate Cancer Foundation.
 2018 Theragnostics Investigator Grant, North American Neuroendocrine Tumor Society.
 2018 Lecturer, International Education Conference, Society of Abdominal Radiology.
 2018 UCSF Health's Exceptional Physician Award, Nominee.
 2019 Alavi-Mandell Award, SNMMI/ERF (co-author/mentor).
 2019 Technologist Best Therapy/Nuclear Oncology Oral Abstract, SNMMI annual meeting (last author/mentor).
 2020 Hal O'Brien Rising Star Award Winner, SNMMI/ERF.
 2022 National Association of State Prostate Cancer Coalitions Honoree.

KEYWORDS/AREAS OF INTEREST:

Novel PET agents, targeted radionuclide therapies, neuroendocrine tumors, prostate cancer, PET/MRI

PROFESSIONAL ACTIVITIES:

Memberships:

2008 – 2017 Society of Computed Body Tomography and Magnetic Resonance (SCBT-MR)
 2018 – 2019 Association of University Radiologists (AUR)
 2006 – present Radiologic Society of North America (RSNA)
 2007 – present International Society of Magnetic Resonance in Imaging (ISMRM)
 2012 – present Society of Abdominal Radiology (SAR)
 2012 – present Society of Nuclear Medicine and Molecular Imaging (SNMMI)
 2016 – present North American Neuroendocrine Tumor Society (NANETS)

Service to Professional Organizations:

2012 – 2018 Liver Imaging Reporting and Data System (LI-RADS), chair of the outreach and education committee, member of the steering committee and hepatobiliary agent subcommittee, American College of Radiology (ACR)
 2013 – 2016 Scientific Program subcommittee, American Roentgen Ray Society (ARRS)
 2015 – 2020 Board Member, PET Center of Excellence, Society of Nuclear Medicine and Molecular Imaging (SNMMI)
 2015 – 2017 Intern, Correlative Imaging Council, Society of Nuclear Medicine and Molecular Imaging (SNMMI)
 2015 – 2020 Chair, PET/MRI Task Force, Society of Nuclear Medicine and Molecular Imaging (SNMMI)
 2016 – 2020 Founding President, PET/MRI Study Group, International Society of Magnetic Resonance in Medicine (ISMRM)
 2016 – 2020 Guidelines Committee, North American Neuroendocrine Tumor Society (NANETS)
 2016 – 2019 Member, Workshop & Study Group Review Committee, International Society of Magnetic Resonance in Medicine (ISMRM)
 2017 Organizing chair, First ISMRM-SNMMI co-provided PET/MRI workshop
 2018 Organizing committee, Coffey Holden Meeting, Prostate Cancer Foundation
 2019 Committee Chair, Second ISMRM-SNMMI co-provided PET/MRI workshop
 2019 Course Director, North American Neuroendocrine Tumor Society (NANETS) Regional NET Education Conference
 2020 Panelist, Clinical Translational Imaging Science, NIH study section

2020 Panelist, NEI Secondary Data Analysis, NIH study section
 2018 – 2021 Neuroendocrine Tumor Task Force, NCI, New Investigator
 2014 – 2023 Chair, Member, Research Committee, Society of Abdominal Radiology (SAR)
 2016 – present Member, Prostate Cancer Disease Focused Panel, Rectal Cancer Disease Focused Panel, Society of Abdominal Radiology (SAR)
 2017 – present President, Vice-President, Board Member, Correlative Imaging Council, Society of Nuclear Medicine and Molecular Imaging (SNMMI)
 2017 – present Alliance in Oncology GI Oncology and Neuroendocrine Tumor panels, member
 2018 – present Vice-President, Treasurer, Board Member, Therapy Center of Excellence, Society of Nuclear Medicine and Molecular Imaging (SNMMI)
 2019 – 2020 Member, Quantitative Imaging in Radiation Therapy Working Group, National Cancer Institute (NCI).
 2019 – 2020 Co-Chair, Neuroendocrine Tumor Clinical Trials Planning Meeting, National Cancer Institute (NCI)
 2020 – present Member, Prostate Cancer Task Force, National Cancer Institute (NCI)
 2020 – present Member, Cancer Imaging Steering Committee, National Cancer Institute (NCI)
 2020 – 2022 Board Member, North American Neuroendocrine Tumor Society (NANETS)
 2023 Panelist, Clinical Translational Imaging Science, NIH study section.

Service to the Institution:

2015 – 2017 Member, Regulatory and Prioritization Subcommittee, Department of Radiology, UCSF
 2015 – 2020 Member, VA Cancer Committee, San Francisco VA Medical Center
 2016 – 2020 Member, Clinical Competency Committee, Department of Radiology, UCSF
 2013 – 2020 Member, MR Safety Committee, San Francisco VA Medical Center
 2014 – present Member, Committee for New Imaging Research, Department of Radiology, UCSF
 2015 – 2023 Member, Cancer Center Clinical Research Oversight Committee, UCSF
 2018 – 2021 Member, VA Radiation Safety Committee, San Francisco VA Medical Center
 2019 – 2023 Member, Clinical Cancer Committee, Helen Diller Family Comprehensive Cancer Center, UCSF
 2019 – present Chair, Molecular Imaging and Radioligand Therapy Site Committee, UCSF
 2020 – present Co-chair, Business Strategy Committee, Department of Radiology, UCSF
 2020 – present Director of Molecular Therapy, Department of Radiology, UCSF
 2020 – 2023 Member, Data and Safety Monitoring Committee, UCSF
 2020 – present Member, CRC Steering Committee, UCSF
 2020 – present Member, Blended Research/Clinical (China Basin) Steering Committee, UCSF
 2020 – present Member, Cyclotron Oversight Committee, UCSF
 2021 – present Chair, VA Radiation Safety Committee, San Francisco VA Medical Center

SERVICE TO PROFESSIONAL PUBLICATIONS

2009 Ad hoc referee, Journal of Heart Valve Disease Review.
 2010 Ad hoc referee, Journal of the American College of Cardiology.
 2008-2013 Ad hoc referee, Magnetic Resonance Imaging.
 2013 Ad hoc referee, Hepatology.
 2014 Ad hoc referee, Bone.
 2015 Ad hoc referee, Investigative Radiology.
 2013-2015 Abstract reviewer, ARRS Annual Meeting.
 2016 Ad hoc referee, Clinical Lung Cancer.
 2008-2016 Abstract reviewer, ISMRM Annual Meeting.
 2015-2016 Ad hoc referee, Abdominal Imaging.
 2017 Distinguished Reviewer, Journal of Magnetic Resonance in Imaging.
 2017-2022 Ad hoc referee, Journal of Urology.
 2009-2017 Ad hoc referee, Journal of Magnetic Resonance in Imaging.
 2017-2018 Ad hoc referee, European Journal of Nuclear Medicine and Molecular Imaging.
 2019 Ad hoc referee, Academic Radiology.
 2019 Ad hoc referee, Radiology: Cardiothoracic Imaging
 2015-2020 Ad hoc referee, American Journal of Roentgenology.
 2020 Ad hoc referee, The Oncologist.
 2016-2021 Editorial Board, Journal of Nuclear Medicine.
 2021 Ad hoc referee, The Lancet.

2014-2022	Ad hoc referee, European Urology.
2015-2022	Ad hoc referee, Journal of Clinical Oncology.
2016-2023	Ad hoc referee, Journal of Nuclear Medicine.
2022	Ad hoc referee, BJU International
2022-present	Associate Editor, Journal of Nuclear Medicine.
2023	Ad hoc referee, Lancet Oncology

INVITED PRESENTATIONS

NATIONAL

1. Fourth Annual Symposium on Nephrogenic Systemic Fibrosis, 2010. Invited talk. "The UCSF experience"
2. Radiologic Society of North America, 2013. Invited talk. "Diffusion and the ADC"
3. Carcinet, 2014. Invited talk. "Ga68 / PRRT Bay Area Update"
4. Radiologic Society of North America, 2014. Invited talk. "Diffusion and the ADC"
5. SNMMI Mid-winter meeting, 2015. Invited talk. "MRI case review: MRI of the body"
6. SNMMI Mid-winter meeting, 2015. Invited talk. "MRI case review: MRI of the brain"
7. Society of Abdominal Radiology Annual Meeting, 2015. Invited talk. "PET/MR for the Body Imager: Applications and Future Prospects"
8. Society of Abdominal Radiology Annual Meeting, 2015. Invited talk. "Complementary Roles of PET and MRI in Local Staging of Rectal Cancer"
9. SNMMI Annual Meeting, 2015. Invited talk. "PET/MRI: Advances in MR Technique"
10. NorCal Carcinet, 2015. Invited talk. "Imaging of Neuroendocrine Tumors"
11. SNMMI Western Regional Meeting, 2015. Invited talk. "PET/MRI: Current Applications with an Eye on the Future"
12. SNMMI Western Regional Meeting, 2015. Invited talk. "Body CT and MRI cases"
13. MD Anderson, Division of Diagnostic Imaging Research Seminar Series, Grand Rounds, 2015. Invited talk. "PET/MRI: Current and Future Applications in Abdominal Malignancies"
14. Radiologic Society of North America, 2015. Invited talk. "Diffusion and the ADC"
15. Radiologic Society of North America, 2015. Invited talk. "LI-RADS 5 vs LI-RADS M"
16. Urology Grand Rounds, UCSF, 2015. Invited talk. "Imaging prostate cancer: where are we going?"
17. SNMMI Advances in Prostate Cancer Imaging, 2016. Invited talk. "PSMA imaging and Radioisotope Therapy"
18. SNMMI Advances in Nuclear Imaging and Therapy for Neuroendocrine Tumors, 2016. Invited talk. "Advances in nuclear imaging for NETs"
19. Bay Area NETs Conference, 2016. Invited talk. "Neuroendocrine Tumors: Approaches to Imaging"
20. SNMMI Mid-Winter Meeting, 2016. Invited talk. "PET/MRI: Applications in Abdominal Malignancies"
21. SNMMI Mid-Winter Meeting, 2016. Invited talk. "Ga-68 DOTA-XXX: imaging and interpretation"
22. SNMMI Mid-Winter Meeting, 2016. Invited talk. "MRI Case Review: MRI of the Body"
23. Northern California Chapter SNMMI Meeting, 2016. Invited talk. "Update on Ga-68 PET Ligands: Current and Future Availability"
24. Society of Abdominal Radiology Annual Meeting, 2016. Invited talk. "Review Experience in PET/MRI of Abdominopelvic Malignancies"
25. Society of Abdominal Radiology Annual Meeting, 2016. Invited talk. "How to Perform and Interpret Diffusion-weighted MRI in Pelvic Oncology"
26. Society of Abdominal Radiology Annual Meeting, 2016. Invited talk. "From OctreoScan to Gallium: The Impact of Targeted Imaging"
27. SNMMI Annual Meeting, 2016. Invited talk. "Conventional Imaging Practices for NETs"
28. SNMMI Annual Meeting, 2016. Invited talk. "PET/MRI in the Evaluation of Pre-Prostatectomy Patients"
29. Visiting Professor, Mayo Clinic, 2016. Invited talk. "Imaging of neuroendocrine tumors"
30. Visiting Professor, Mayo Clinic, 2016. Invited talk. "PSMA PET"
31. TMII (Translational and Molecular Imaging Institute) Lecture, Mt. Sinai, 2016. Invited talk. "Abdominopelvic PET/MRI"
32. SNMMI Western Regional Meeting, 2016. Invited talk. "New Developments in PET/MRI"
33. Radiologic Society of North America, 2016. Invited talk. "Hepatocellular Carcinoma in the Cirrhotic Liver and LI-RADS: Cases"
34. Radiologic Society of North America, 2016. Invited talk. "PET/MRI Clinical Applications: Body"
35. American Society of Clinical Oncology, GI cancers symposium, 2017. Invited talk. "⁶⁸Ga-DOTA-TATE PET Imaging of Neuroendocrine Tumors and Beyond"

36. American Society of Clinical Oncology, GI cancers symposium, 2017. Panelist. "Neuroendocrine Tumors—Practical Applications of Emerging Treatment Options"
37. SNMMI Mid-Winter Meeting, 2017. Invited talk. "MRI Case Review: MRI of the Body"
38. Cancer Support Community San Francisco Bay Area, 2017. Invited talk. "Ga-PSMA at UCSF"
39. Sixth Annual Bay Area NET Patient Education Conference, 2017. Invited talk. "Peptide Receptor Radionuclide Therapy (PRRT)"
40. 39th Annual High Country Nuclear Medicine Conference, 2017. Invited talk. "68Ga-PSMA-11: Experience in the US"
41. University of Washington, Imaging Research Laboratory, 2017. Invited talk. "Imaging and Treatment of Neuroendocrine Tumors"
42. University of Washington, Prostate SPORE Seminar, 2017. Invited talk. "PSMA PET and its role in prostate cancer"
43. Society of Abdominal Radiology Annual Meeting, 2017. Invited talk. "Multiparametric MRI for the Evaluation of Prostate Cancer Recurrence"
44. American Pharmacists Association Annual Meeting, 2017. Invited talk. "PSMA PET in patients with prostate cancer"
45. Radiology Grand Rounds, Boston University, 2017. Invited talk. "Imaging and Treatment of Neuroendocrine Tumors"
46. Clinical Trials Network, Society of Nuclear Medicine and Molecular Imaging, 2017. Invited talk. "Ga-PSMA for Prostate Cancer: US Status"
47. Pathways for Successful Translation of New Imaging Agents and Modalities: Phase III Studies, National Cancer Institute, 2017. Invited talk. "PSMA targeted PET probes for prostate cancer"
48. International Society of Magnetic Resonance in Imaging, 2017. Invited talk. "Current Clinical Applications, Novel Tracers, and Future Directions"
49. Society of Nuclear Medicine and Molecular Imaging, 2017. Invited talk. "Imaging of Neuroendocrine Tumors"
50. Forum for Advanced Imaging Research, UCSF Department of Radiology, 2017. Invited talk. "PET/MRI: A Successful Translation to the Clinic"
51. San Jose Prostate Cancer Support Group, 2017. Invited talk. "PSMA for the imaging and treatment of patients with prostate cancer"
52. Precision Imaging in Cancer and Therapy Symposium, UCSF, 2017. Invited talk. "Clinical translation of targeted imaging and therapies for neuroendocrine tumors"
53. Radiation Oncology Grand Rounds, UCSF, 2017. Invited talk. "PSMA for the imaging and treatment of patients with prostate cancer"
54. State of the Science Summit, OncLive, 2017. Invited talk. "Moving Cancer Imaging into the 21st Century"
55. Second Global Summit on Precision Diagnosis For Prostate Cancer Care (AdMeTech), 2017. Invited Talk. "Experience with PSMA PET at UCSF"
56. Osher Mini Medical School, 2017. Invited Talk. "PSMA for the imaging and treatment of patients with prostate cancer"
57. Osher Mini Medical School, 2017. Invited Talk. "Targeted imaging and therapy in neuroendocrine tumors"
58. North American Neuroendocrine Tumor Society, 2017. Invited Talk. "Consensus & Controversy: Lessons from the Appropriate Use Criteria Delphi Consensus Process"
59. North American Neuroendocrine Tumor Society, 2017. Invited Talk. "Personalizing Therapy for NETs with Functional Imaging - Where Do Things Stand in 2017"
60. ISMRM/SNMMI co-provided Workshop on PET/MRI, 2017. Invited Talk. "Introduction to Staging of Prostate Cancer"
61. ISMRM/SNMMI co-provided Workshop on PET/MRI, 2017. Invited Talk. "Closing Comments"
62. Radiologic Society of North America, 2017. Invited talk. "PET/MRI Clinical Applications: Body"
63. Radiologic Society of North America, 2017. Invited talk. "Somatostatin Receptor PET: Case review"
64. Radiologic Society of North America, 2017. Instructor. "Case Review: Introduction to LI-RADS (Hands-on)"
65. Radiology Grand Rounds, University of California, San Diego, 2017. Invited Talk. "Advances in imaging of prostate cancer with PSMA PET"
66. San Diego Radiological Society, 2017. Invited Talk. "Imaging and Treatment of Neuroendocrine Tumors"
67. 2018 Bay Area Neuroendocrine Patient Conference, 2018. Invited talk. "Imaging Basics"
68. SNMMI Mid-Winter Meeting, 2018. Invited talk. "The Role of IA PRRT in Neuroendocrine Tumors"
69. SNMMI Mid-Winter Meeting, 2018. Invited talk. "Development of the SSTR-PET Appropriate Use Criteria"
70. Society of Abdominal Radiology Annual Meeting, 2018. Invited talk. "Molecular Imaging Beyond FDG"
71. Society of Abdominal Radiology Annual Meeting, 2018. Invited talk. "Hypervascular Tumors: The Many Faces of Melanoma and Neuroendocrine Tumors"

72. American Urological Society, 2018. Invited talk. "Prostate Cancer: What PET to Get?"
73. American Urological Society, 2018. Invited talk. "Imaging of Biochemical Recurrence"
74. American Brachytherapy Society, 2018. Invited talk. "Prostate Cancer: PET Based Imaging"
75. NANETS Regional NET Education, 2018. Invited talk. "Embolic and Minimally Invasive Treatments for Liver Metastases"
76. NANETS Regional NET Education, 2018. Invited talk. "Imaging Modalities for Diagnosis of Follow-up: Anatomic and Functional Imaging"
77. Society of Nuclear Medicine and Molecular Imaging, 2018. Invited talk. "PET/MRI Hybrid Imaging: The Technologist's Latest Friend"
78. Society of Nuclear Medicine and Molecular Imaging, 2018. Invited talk. "SSTR-PET AUC"
79. PET/MRI Users Meeting, 2018. Invited talk. "Clinical results with the SIGNA PET/MR with QuantWorks"
80. PET/MRI Users Meeting, 2018. Invited talk. "Oncology: Body Imaging"
81. American Association of Physicists in Medicine, 2018. Invited talk. "Quantitative Inaccuracy in PET/MRI: Is It Real and When Does it Matter"
82. Radiation Oncology Grand Rounds, UCSF, 2018. Invited talk. "Advances in Imaging and Treatment of Prostate Cancer"
83. Imaging Grand Rounds, Cedars Sinai, 2018. Invited talk. "Advances in Nuclear Medicine: The Move to Theranostics"
84. El Camino Hospital, Grand Rounds, 2018. Invited Talk. "Targeted Imaging and Therapy in NETs"
85. Imaging Staff, Cedars Sinai, 2018. Invited talk. "Advances in Nuclear Medicine: The Move to Theranostics"
86. North American Neuroendocrine Tumor Society, 2018. Invited Talk. "Appropriate Use Criteria for Ga68-SSTR-PET"
87. Radiologic Society of North America, 2018. Invited talk. "PET/MRI Update 2018: Body"
88. Radiologic Society of North America, 2018. Invited talk. "Somatostatin Receptor PET & Therapy"
89. Radiology Grand Rounds, University of Maryland, 2018. Invited Talk. "PET/MRI: Moving Forward Successfully"
90. Marin Cancer Center, 2019. Invited Talk. "Targeted Imaging and Therapy in NETs"
91. Neuroendocrine Tumor Patient Conference, 2019. Invited Talk. "PRRT: Where are now and what's on the horizon?"
92. Neuroendocrine Tumor Patient Conference, 2019. Invited Talk. "Imaging Basics: CT - MRI - SPECT – PET"
93. General Surgery Grand Rounds, UCSF, 2019. Invited Talk. "Putting Down the Scalpel: Updates in Rectal Cancer Management."
94. Epic Care, 2019. Invited Talk. "Targeted Imaging and Therapy in NETs"
95. NCI Quantitative Imaging for Radiation Therapy, 2019. Invited Talk. "Lu-177 Based Priming of Immunogenic Response."
96. UCSF Patient Conference on Prostate Cancer, 2019. Invited Talk. "Molecular Imaging in Prostate Cancer"
97. Society of Nuclear Medicine and Molecular Imaging, 2019. Invited talk. "Imaging Prostate Cancer with PSMA PET."
98. Society of Nuclear Medicine and Molecular Imaging Webex, 2019. Invited talk. "NANETS-SNMMI Procedure Guidelines."
99. Memorial Sloan Kettering Cancer Center, Molecular Imaging and Therapy Seminar, 2019. Invited talk. "Struggling to Understand How to Optimize Personalized Therapy in The Era of Theranostics."
100. North American Neuroendocrine Tumor Society, 2019. Invited Talk. "North American Neuroendocrine Tumor Society, 2018. Invited Talk. "Appropriate Use Criteria for Ga68-SSTR-PET."
101. Fourth Global Summit on Precision Diagnosis For Prostate Cancer Care (AdMeTech), 2019. Invited Talk. "PSMA-11 PET: Atypical Paths to FDA Approval and Academic NDAs."
102. ISMRM/SNMMI co-provided Workshop on PET/MRI, 2019. Invited Talk. "Imaging of Prostate Cancer"
103. North American Neuroendocrine Tumor Society (NANETS) Regional NET Education Conference, 2019. Invited Talk. "Imaging in NETs"
104. North American Neuroendocrine Tumor Society (NANETS) Regional NET Education Conference, 2019. Invited Talk. "Introduction and Review of NETs"
105. North American Neuroendocrine Tumor Society (NANETS) Regional NET Education Conference, 2019. Invited Talk. "NET Tumor Board Cases"
106. SNMMI/NCI Third Targeted Radionuclide Therapy Conference, 2019. Invited Talk. "Toxicity in TRT"
107. SNMMI Mid-Winter Meeting, 2020. Invited Talk. "PSMA PET/CT and PET/MRI for prostate cancer"
108. Society of Abdominal Radiology Annual Meeting, 2020. Invited talk. "Prostate PET/MRI: Which Agent to Use When"
109. Society of Abdominal Radiology Annual Meeting, 2020. Invited talk. "Advances in Imaging of Prostate Cancer"

110. 2020 Reynolds Talk (University of Texas, South Western Grand rounds), 2020. Invited talk. "Imaging and Treating Patients with PSMA Targeted Agents"
111. SNMMI Annual Meeting, Patient Education Day, 2020. Invited talk. "Radiation Safety with Targeted Radionuclide Therapy"
112. SNMMI Annual Meeting, Patient Education Day, 2020. Invited talk. "The Basics: How Theranostics Works?"
113. Master of Translational Medicine Program, UC Berkeley, 2020. Invited talk. "PET imaging in cancer with a focus on prostate"
114. Developing and Strengthening Your Academic Radiology Research Career, UCSF, 2020. Department talk. "Clinical Trial Workflow Through Two Examples"
115. Chicagoland Radiology Expo, 2020. Invited talk. "Body Imaging: Molecular Imaging in the Abdomen and Pelvis"
116. Radiologic Society of North America, 2020. Invited talk. "Molecular Imaging of Prostate Cancer for Biochemical Recurrence and Metastatic Disease"
117. Society of Nuclear Medicine and Molecular Imaging Webex, 2021. Invited talk. "Introduction to the PSMA NDA"
118. Northwestern Radiology Grand Rounds, 2021. Invited talk. "Imaging and Treating Patients Targeting PSMA"
119. NCI NET CTPM, 2021. Invited talk. "Measurements for Dosimetry"
120. Coalition to Improve Access to Diagnostic Imaging, 2021. Invited Talk "Impact of PET Imaging"
121. 43rd Annual High Country Nuclear Medicine Conference, 2021. Invited talk. "Status of PSMA Imaging in the US"
122. Dana-Farber Genitourinary Oncology Seminar Series, 2021. Invited talk. "PSMA PET and Radioligand Therapy"
123. Winship Cancer Institute Grand Rounds (Emory), 2021. Invited talk. "PSMA and Moving Forward with Imaging and Therapy"
124. UC Irvine Radiology Grand Rounds, 2021. Invited Talk. "Advances in Imaging and Therapy of Prostate Cancer"
125. UC Irvine Radiology Resident Conference, 2021. Invited Talk. "Nuclear Medicine Cases"
126. Society of Nuclear Medicine and Molecular Imaging Annual Meeting, 2021. Invited talk. "Appropriate Use Guidelines for PRRT."
127. Society of Nuclear Medicine and Molecular Imaging Annual Meeting, 2021. Invited talk. "Tumor Board Cases."
128. Michigan Urologic Surgery Improvement Collaborative (MUSIC) Urology, 2021. Invited talk. "Current Status of PSMA PET in the US."
129. American Urologic Association Summer School, 2021. Invited talk. "PSMA PET and Prostate Cancer"
130. Los Angeles Carcinoid Neuroendocrine Tumor Society (LACNETS) Annual Meeting, 2021. Invited talk. "Radiation Safety with PRRT."
131. Yale Center For GI Cancers Weekly Seminar, 2021. Invited talk. "NETs and PRRT: Overview and Workflow."
132. American Urologic Association International Prostate Forum, 2021. Invited talk. "PSMA is here..."
133. The Academy Coalition for Imaging and Bioengineering Research, 2021. Invited talk. "Introduction to Theranostics"
134. Society of Urologic Oncology, 2021. Invited talk. "Integrating Imaging into Prostate Cancer Care"
135. Radiological Society of North America, 2021. Invited talk. "Molecular Imaging in Prostate Cancer (PSMA PET)"
136. SNMMI Mid-Winter Meeting, 2022. Invited talk. "Initial Experience with FAP-2286 Imaging"
137. SNMMI Mid-Winter Meeting, 2022. Invited talk. "Improving on Current Practice: PRRT Moving Forward"
138. Grand Rounds in Urology, International Prostate Cancer Update, 2022. Invited talk. "Appropriate Use of PSMA PET in Clinical Practice"
139. Great Debates and Updates in Genitourinary Malignancy, 2022. Invited talk. "Advances in Prostate-Specific Membrane Antigen (PSMA) Imaging: Focus on Biochemical Recurrence"
140. SNMMI Therapeutics Conference, 2022. Invited talk. "Next Generation PET Imaging in Prostate Cancer"
141. SNMMI Therapeutics Conference, 2022. Invited talk. "Research Cooperative Groups"
142. American Urologic Association Annual Meeting, 2022. Invited talk. "PSMA PET: how we use it"
143. ASCO (American Society of Clinical Oncology) Annual Meeting, 2022, Invited talk. "Molecular Based Imaging: Redefining the Disease Landscape"

144. Nebraska Oncology Society, Annual Midwest Regional ASCO Review 2022, Invited talk. "Molecular Based Imaging: Redefining the Disease Landscape"
145. Los Angeles Carcinoid Neuroendocrine Tumor Society (LACNETS) Annual Meeting, 2022. Invited talk. "The Latest in NET imaging and PRRT"
146. National Association of State Prostate Cancer Coalitions (NASPCC) Annual Meeting 2022. Invited talk. "PSMA-Lutetium and Theranostics"
147. National Association of State Prostate Cancer Coalitions (NASPCC) Annual Meeting 2022. Invited talk. "PSMA PET and Functional Imaging"
148. Emory University Radiology 2022, Invited talk. "Molecular Based Imaging Redefining the Disease Landscape"
149. Emory University Radiology Grand Rounds 2022, Invited talk. "Struggling with the Theranostic Wave"
150. Mt. Sinai Case Conference 2022, Invited talk. "Interesting Case Conference"
151. Mt. Sinai Radiology Grand Rounds 2022, Invited talk. "Struggling with the Theranostic Wave"
152. NCI Patient Advocate Steering Committee 2023, Invited talk. "Imaging in Clinical Trials"
153. High Country Nuclear Medicine Conference 2023, Invited talk. "PSMA Radioligand Therapy"
154. Society of Nuclear Medicine and Molecular Imaging 2023, Invited talk. "Current State of Clinic Trials with Targeted Alpha Therapies."
155. Society of Nuclear Medicine and Molecular Imaging 2023, Invited talk. "PSMA PET Cases"
156. Society of Nuclear Medicine and Molecular Imaging 2023, Invited talk. "PSMA RLT Cases"
157. Dana Farber Joint Program in Nuclear Medicine 2023, Invited Talk. "Case Conference"
158. Dana Farber Second Annual Kircher Lecture 2023, Invited talk. "Seeing what you're treating: is that precision medicine?"
159. Princess Margaret Cancer Center High Definition Therapeutics Symposium, Invited talk. "Seeing what you're treating: is that precision medicine?"

INTERNATIONAL

1. 4D flow symposium, Oxford, England, 2013. Invited talk. "Flow profile analysis"
2. American Roentgen Ray Society, Toronto, Canada, 2015. Invited talk. "Hepatobiliary Agents"
3. Radiology Asia, Singapore, 2015. Invited talk. "MRI of Hepatocellular Carcinoma: Technique and LI-RADS"
4. Radiology Asia, Singapore, 2015. Invited talk. "PET/MRI for Evaluation of Abdominal Malignancies"
5. PET/MRI Users Meeting, Uppsala, Sweden, 2015. Invited talk. "Grand Rounds – Oncology"
6. PET/MRI Users Meeting, Uppsala, Sweden, 2015. Invited talk. "Pediatric Applications"
7. International Conference on Radiation Medicine, Saudi Arabia, 2016. Invited Talk "PET/MRI role in pelvic malignancies and prostate cancer"
8. International Conference on Radiation Medicine, Saudi Arabia, 2016. Invited Talk "PET/MRI in neuroendocrine tumors"
9. International Conference on Radiation Medicine, Saudi Arabia, 2016. Invited Talk "Current status of clinical PET/MRI: where do we stand?"
10. International Society of Magnetic Resonance in Imaging, Singapore, 2016. Invited Talk "Oncological PET/MRI: Where Will it Replace PET/CT?"
11. New Perspectives in Molecular Imaging, ITEL. Italy, 2016. Invited Talk "68Ga-DOTA-TOC imaging for staging of NETs"
12. International Symposium of PET/MR, Taiwan Oncology Society. Taiwan, 2017. Invited Talk "PET/MR of Prostate Cancer"
13. International Symposium of PET/MR, Taiwan Oncology Society. Taiwan, 2017. Invited Talk "PET/MR: Technical Developments"
14. First Mediterranean PET/MR Conference. Tel Aviv, 2018. Invited Talk "Non FDG PET/MR in Clinical Oncology and Beyond"
15. European Society of Urogenital Radiology. Barcelona, 2018. Invited Talk "SAR Honorary Lecture - Advances in molecular imaging for urogenital cancers"
16. Faculty of Radiologists Annual Scientific Meeting, Dublin Ireland, 2018. Invited Talk "PET/MRI in pelvic malignancies"
17. Faculty of Radiologists Annual Scientific Meeting, Dublin Ireland, 2018. Invited Talk "Imaging of Prostate Cancer Using PSMA PET"
18. Faculty of Radiologists Annual Scientific Meeting, Dublin Ireland, 2018. Invited Talk "Gadoxetate technique"
19. Faculty of Radiologists Annual Scientific Meeting, Dublin Ireland, 2018. Invited Talk "LI-RADS Tips"
20. Faculty of Radiologists Annual Scientific Meeting, Dublin Ireland, 2018. Invited Talk "Imaging of neuroendocrine tumors"

21. Faculty of Radiologists Annual Scientific Meeting, Dublin Ireland, 2018. Invited Talk "Peptide Receptor Radionuclide Therapy"
22. Faculty of Radiologists Annual Scientific Meeting, Dublin Ireland, 2018. Invited Talk "Rectal Cancer Imaging"
23. Japanese Society of Nuclear Medicine, Matsuyama Japan, 2019. Invited Talk "Invited Talk "Diagnostic Ability of 68-Ga PSMA PET for Prostate Cancer""
24. Japanese Society of Nuclear Medicine, Matsuyama Japan, 2019. Keynote Talk "Theranostics: an update version 2019"
25. ProSTIC Peter MacCallum, Melbourne Australia, 2022. Invited Talk "Global clinical trial landscape"
26. ProSTIC Peter MacCallum, Melbourne Australia, 2022. Invited Talk "Best practice PSMA PET/CT: accepted use criteria, standardized reporting"
27. ProSTIC Peter MacCallum, Melbourne Australia, 2022. Invited Talk "Spoilt for choice with Ga-68 PSMA-11, F-18 DCFPyL & F-18 PSMA-1007: is there a difference?"
28. SNMMI Annual Meeting, Vancouver Canada, 2022. Invited talk. "Debate (Con): Dosimetry should be used in clinical radiopharmaceutical therapies."
29. Japanese Pancreas Society, 2022. Invited talk. "The role of PRRT in pancreatic NETs" (*virtual*)
30. Tanzanian Surgical Society's First Colorectal Cancer Symposium, 2022. Invited talk. "Imaging Rectal Cancer" (*virtual*)
31. International Diagnostic Course Davos, 2023. Invited talk. "Advances in Molecular Imaging and Therapy and Its Impact in Oncologic Imaging"
32. International Diagnostic Course Davos, 2023. Invited talk. "The Future of Molecular Imaging: Impact on Cancer Diagnosis and Therapy"

CME TALKS

1. UCSF Radiology Review: Clinical Highlights, 2013. "MR Enterography"
2. UCSF Radiology Review: Annual Review, 2014. "Focal Liver Lesions"
3. UCSF Radiology Review: Clinical Highlights, 2014. "MR Enterography"
4. UCSF Radiology Review: Annual Review, 2015. "Focal Liver Lesions"
5. UCSF Radiology Review: Annual Review, 2016. "Nuclear Medicine: Whole Body Oncology"
6. UCSF Radiology Review: Annual Review, 2016. "Nuclear Medicine: Gastrointestinal"
7. UCSF Radiology Review: Annual Review, 2016. "Imaging the liver"
8. UCSF Radiation Oncology Annual Course, 2017. "PET imaging in prostate cancer"
9. UCSF Prostate Cancer Imaging Workshop, 2017. "Imaging Biochemical Recurrence"
10. UCSF Radiology Review: Annual Review, 2017. "Nuclear Medicine: Whole Body Oncology"
11. UCSF Radiology Review: Annual Review, 2017. "Nuclear Medicine: Gastrointestinal"
12. UCSF Radiology Review: Annual Review, 2017. "Imaging the liver"
13. UCSF Prostate Cancer Imaging Workshop, 2018. "Imaging Biochemical Recurrence"
14. UCSF Radiology Review: Annual Review, 2018. "Imaging the liver"
15. UCSF Prostate Cancer Imaging Workshop, 2018. "Imaging Biochemical Recurrence"
16. Imaging Update in Wine Country, 2018. "Imaging of Neuro-endocrine Tumors"
17. Imaging Update in Wine Country, 2018. "Imaging Advances in Prostate Cancer"
18. Imaging Update in Wine Country, 2018. "LI-RADS Update"
19. Imaging Update in Wine Country, 2018. "Tips in Liver Imaging"
20. Imaging Update in Wine Country, 2018. "Rectal Cancer Imaging"
21. Imaging Update in Wine Country, 2018. "Rapid Body/Nucs Cases with Audience Response"
22. Body Imaging in Kona, 2019. "Imaging of Biochemically Recurrent Prostate Cancer"
23. Body Imaging in Kona, 2019. "Hepatobiliary Agents and Their Role in Liver Imaging"
24. Body Imaging in Kona, 2019. "LI-RADS Cases"
25. Body Imaging in Kona, 2019. "Imaging of Rectal Cancer"
26. Body Imaging in Kona, 2019. "Imaging of Neuroendocrine Tumors"
27. UCSF Radiology Review: Annual Review, 2019: "Imaging the Liver"
28. Diabetes Update and Advances in Endocrinology and Metabolism, 2019. "Nuclear imaging in endocrine diseases"
29. Abdominal & Pelvic Imaging in Palm Springs, 2020. "Imaging Response to Immunotherapy"
30. Abdominal & Pelvic Imaging in Palm Springs, 2020. "Imaging of Recurrent Prostate Cancer"
31. Abdominal & Pelvic Imaging in Palm Springs, 2020. "Imaging of Neuroendocrine Tumors"
32. Abdominal & Pelvic Imaging in Palm Springs, 2020. "MRI for Rectal Cancer"
33. UCSF Radiology Review: Annual Review, 2021. "Imaging the liver"

OTHER TALKS

1. UroToday, 2020. "PSMA PET in Prostate Cancer"
2. UroToday, 2020. "Radiation Safety with Targeted Radionuclide Therapy"
3. HDFCCC PI Talk, 2021. "An Academic NDA: Our Path with PSMA PET"
4. Prostate Cancer Research Institute, 2021. Invited talk. "Prostate Cancer and PSMA PET"
5. SSO Virtual Tumor Board, 2021. Expert panelist. "PRRT in Advanced Neuroendocrine Tumors"
6. ACNM Nuclear Medicine Resident Organization Virtual Journal Club, 2021. Faculty mentor. "PSMA PET"
7. Carcinoid Cancer Foundation, 2022. "Luncheon with the Experts"
8. National Alliance of State Prostate Cancer Coalitions Webinar Series, 2022. "Overview of Prostate Cancer Imaging"
9. Alliance Spring Meeting, 2022. "Clinical Research Professionals for A021901 (neuroendocrine)"
10. UCSF Prostate Cancer Program 2022 Scientific Retreat, 2022. "PSMA PET and Radioligand Therapy"

TEACHING

I enjoy both informal clinical teaching and delivering formal clinical and research-oriented lectures. For resident education, I have given lectures during the resident conferences as well as have given dedicated case based reviews of nuclear medicine to residents for board preparation. I have given lectures in the UCSF Resident Review course as well as the Clinical Highlights course. I have also developed a hands-on MRI training course for incoming Abdominal Imaging fellows in conjunction with Michael Ohliger, that has been given in 2014-2017. I have given numerous talks on imaging of hepatocellular carcinoma, neuroendocrine tumors, prostate cancer and PET/MRI.

UCSF RESIDENT LECTURES

Diffuse Liver Disease, January 2014.
Lymphoma Overview, March 2014.
Nuclear Medicine: Gastrointestinal, April 2014.
LI-RADS, June 2014.
Neuroendocrine Tumors, July 2014.
Thyroid Cancer, November 2014.
Radium-223, February 2015.
Imaging Prostate Cancer: where are we going? December 2015.
Rectal Cancer: review of imaging approaches, October 2015.
Nuclear Medicine Cases, June 2016.
LI-RADS, August 2016.
Peptide Receptor Radionuclide Therapy, January 2017.
Hepatocellular Carcinomas: LI-RADS, July 2017.
Imaging of Neuroendocrine Tumors, October 2017.
Rectal Cancer: review of imaging approaches, July 2018.
LI-RADS cases, October 2018.
Review of Radioligand Therapy, December 2018.
Nuclear Medicine: Gastrointestinal, April 2019.
Diffusion and the ADC, September 2019.
T1 and K-space, October 2019.
Imaging of Immunotherapy, October 2019.
68Ga-PSMA-11 PET in prostate cancer, November 2019.
Nuclear Medicine Cases, January 2020.
Radium-223, May 2020.
PET/MRI technical development, May 2020.
Nuclear Medicine Cases, June 2020.
Spin Echo Sequences, August 2020.
Imaging and Therapy of Neuroendocrine Tumors, September 2020.
Nuclear Medicine: Gastrointestinal, May 2021.
Thyroid Cancer, September 2021.
Radium-223 in Prostate Cancer, September 2021.
Nuclear Medicine: Gastrointestinal, April 2022.
PSMA PET and PSMA Radioligand Therapy, August 2022.
Nuclear Medicine: Gastrointestinal, May 2023.

Thetanostics, September 2023.

TEACHING LECTURES (NON-RESIDENT)

Imaging in Oncology, Oncology fellows, UCSF, February 6th, 2015
Liver MRI, Surgical residents, UCSF, August 2nd, 2015
Imaging of HCC, Transplant hepatology fellows, UCSF, June 19th, 2015
MRI contrast agents, Neuroradiology fellows, UCSF, August 3rd 2015
Imaging in Oncology, Oncology fellows, UCSF, November 16th, 2015
PET and MRI in Prostate Cancer, UCSF FAIR (Forum for Advanced Imaging Research), April 20th, 2016
Imaging of Liver Tumors, Transplant hepatology fellows, UCSF, April 22nd 2016
Ga68-PSMA: experience at UCSF, Prostate Cancer Foundation Imaging Group, June 20th, 2016
Targeted imaging in oligometastatic disease, Urology Research in Progress, UCSF, June 22nd, 2016
MRI contrast agents, Neuroradiology fellows, UCSF, July 25th 2016
Somatostatin receptor PRRT, Nuclear medicine technologists, UCSF, September 8th, 2016
PSMA at UCSF, Urology Team, UCSF, September 9th, 2016
Liver MRI, Surgical residents, UCSF, October 5th, 2016
Imaging of Non-HCC Tumors, Transplant hepatology fellows, UCSF, June 2nd 2017
Imaging in Oncology, Oncology fellows, UCSF, October 2nd, 2017
NET Targeting Imaging and Therapy, Mission Bay Hospital Nursing, UCSF, October 2nd, 2017
Somatostatin Receptor PET, UCSD Radiology Residents, December 5th, 2017
Surgical Anatomy, UCSF Medical Student Radiology lecture series, July 25th, 2018
Surgical Anatomy, UCSF Medical Student Radiology lecture series, September 12th, 2018
Imaging in Oncology, Oncology fellows, UCSF, August 12th, 2019
Introduction to Theranostics, UCSF FAIR (Forum for Advanced Imaging Research), August 12th, 2020
Imaging in Oncology, Oncology fellows, UCSF, August 17th, 2020
Imaging of Rectal Cancer, Surgical Residents, UCSF, October 26th, 2020
Imaging of Rectal Cancer, Surgical Residents, UCSF, December 28th, 2020
PSMA PET and Radioligand Therapy, Radiation Oncology Residents, UCSF, March 29th, 2021
Imaging of Rectal Cancer, Surgical Residents, UCSF, June 24th, 2021
Imaging in Oncology, Oncology fellows, UCSF, August 16th, 2021
PSMA PET and Radioligand Therapy, Radiation Oncology Residents, UCSF, April 4th, 2022
Imaging of Rectal Cancer, Surgical Residents, UCSF, March 16th, 2022
Imaging of Rectal Cancer, Surgical Residents, UCSF, April 20th, 2022
PET/MRI, Abdominal Imaging Fellows, UCSF, August 12th, 2022
Imaging in Oncology, Oncology fellows, UCSF, November 14th, 2022
Discussion of Current State, Nuclear Medicine Fellows, UCSF, September 15th, 2023

LIST OF UCSF RESIDENTS AND FELLOWS I HAVE SUPERVISED/MENTORED

Sarasa Kim (Resident)
Andrew Taliaferro (Resident)
Kirti Magrudi (AI Fellow)
David Lin (Nuclear medicine fellow)
Roxanna Juarez (Nuclear medicine fellow)
Uzoezi Ozomaro (Nuclear medicine fellow)
Yan Li (Resident)
Spencer Lake (Resident)
Colin Burke (Resident)
Robert Hicks (Resident)
Jason Bailey (AI Fellow)
Eric Jordan (AI Fellow)
Jennifer Lee (AI Fellow)
Eugene Hao (AI Fellow)
Donald Kim (AI Fellow)
Kareem Mawad (AI Fellow)
Bernice Lau (AI Fellow)
Jao Ou (AI Fellow)
Jenny Lu (AI Fellow)

Susana Candia (AI Fellow)
 Brett Mollard (AI Fellow)
 Nicholas Monu (AI Fellow)
 Kai Kinder (AI Fellow)
 Brian Bentley (AI Fellow)
 Lisa Chu (AI Fellow)
 David Valenzuela (AI Fellow)
 Hakeem Afuwape (AI Fellow)
 Harpreet Dhatt (AI Fellow)
 Jeremiah Boyd (AI Fellow)
 Sonia Lee (AI Fellow)
 Jeffrey Kao (AI Fellow)
 Shilpa Puppala (AI Fellow)
 Priyanka Jha (AI Fellow)
 Shital Ghandi (AI Fellow)
 Robert Flavell (Nuclear Medicine Fellow)
 Benjamin Laguna (Resident)
 Nabia Ikram (AI fellow)
 Evan Lehrman (AI fellow)
 Nick Burriss (Resident)
 Mark Kovacs (AI fellow)
 Eric Ehman (Resident)
 Sandeep Arora (AI fellow)
 Bilal Ahmed (AI fellow)
 Niv Decalo (AI fellow)
 Lauren Hollowell (AI fellow)
 Alexander Keedy (AI fellow)
 Jasmin Koohi (AI fellow)
 John Mongan (AI fellow)
 Brian Park (AI fellow)
 Phillip Reich (AI fellow)
 Derek Sun (AI fellow)
 William Theodorou (AI fellow)

LIST OF PERSONNEL OUTSIDE OF RESIDENCY/FELLOWSHIP I HAVE SUPERVISED/MENTORED

Dominique Escobar (UCSF Urology Resident / T32 Fellow)
 Amir Iravani (Washington University Radiology Faculty)
 Sean Wollen (UCSF Abdominal Imaging Faculty)
 Benjamin Wildman-Tobriner (Duke University Radiology Faculty)
 Elizabeth Smith (Data Science Health Innovation Fellow)
 Ivan de Kouchkovsky (Hematology Oncology Fellow)
 Vadim Koshkin (GU Medical Oncology faculty)
 Roxanna Juarez (Radiology Faculty, Nuclear medicine fellow)
 Samuel Washington (Urology Faculty)
 Courtney Lawhn-Heath (Radiology Faculty, Resident)
 Matthew Bucknor (Radiology Faculty)
 Michael Ohliger (Radiology Faculty)
 Robert Johnson (Nuclear Medicine Technologist)
 Navkanwal Daljit (Nuclear Medicine Technologist)
 Jeffrey Rinker (Nuclear Medicine Technologist)
 Vishnu Murthy (Clinical Research Coordinator)
 Julia Whitman (Clinical Research Coordinator)
 Thomas Oloughlin (Post-doctoral scientist)
 Raven Smith (Clinical Research Coordinator)
 Erika Padilla-Morales (Nuclear Medicine Technologist)
 Andrew Leynes (PhD Student)
 Sarah Umetsu (Pathology Fellow)
 Jeremy Goodman (UCSF Medical Student)

Bryant Chee (GI Onc Clinical Research Coordinator)
Emily Verdin (Clinical Research Coordinator)
Wenwen Jiang (Research Scientist)
Charmaine Santos (Undergraduate Student)
Paola M. Perez (UCSF Medical Student)
Susan Wu (Radiation Oncology Resident)
Lauren Boreta (Radiation Oncology Resident)
Adam Gadzinski (Urology Resident)
Jaewon Yang (Post-doctoral Scientist)
Yun Rose Li (Radiation Oncology Resident)
Melody Xu (Radiation Oncology Resident)
Ali Salavati (Radiology Resident from University of Minnesota)

RESEARCH AND CREATIVE ACTIVITIES

RESEARCH AWARDS AND GRANTS

Current

1. R01CA235741 (NIH NCI R01)
7/1/2019 – 6/30/2024
MELT: Modulation of PSMA Expression for Lutetium Therapy
Role: Principal Investigator.
2. R01CA212148 (NIH NCI R01)
3/6/2017 – 2/28/2022
Qualification and Harmonization of PET/MRI for Cancer Clinical Trials.
Role: Principal Investigator.
3. Clovis Oncology IIT
1/1/2021 – 12/31/2022
Imaging of Solid Tumors Using 68Ga-FAP-2286
Role: Principal Investigator

Past

1. 1R01CA229354 (NIH NCI R01)
6/1/2019 – 4/30/2021
Immunogenic Priming with Lu-PSMA Targeted Therapy in Advanced Prostate Cancer
Role: Co-Principal Investigator
2. NANETS Theragnostics Investigator Grant
10/1/2018 – 9/30/2020
Optimization of Intra-Arterial Y90-DOTATOC PRRT
Role: Principal Investigator
3. R01EB024014 (NIH NIBIB R01)
9/20/2017 – 6/30/2021
Clinical Translation of D-Amino Acid Derived Pet Tracers for Imaging Spinal Infection.
Role: Co-investigator.
4. R01EB025985 (NIH NIBIB R01)
5/1/2018 – 1/31/2022
Development of 11C-PAVA as a Bacteria-Specific Imaging Agent for Spinal Infections.
Role: Co-investigator.
5. Prostate Cancer Foundation Challenge Award

8/1/2018 – 7/31/2020

Mechanisms of resistance to PSMA radioligand therapy in Phase III study: radiation resistance versus dose.

Role: Principal Investigator.

6. Prostate Cancer Foundation Young Investigator Award

7/1/2017 – 6/30/2020

Redefining M0 CRPC patients using PSMA PET.

Role: Principal Investigator.

7. Nuclear Medicine Pilot Research Grant in NETS

7/1/2017 – 6/30/2018

Intra-Arterial Peptide Receptor Radionuclide Therapy (IA-PRRT) using 90Y-DOTA-TOC.

Role: Principal Investigator.

8. Margie & Robert E. Petersen Foundation – Sunderland (PI)

12/1/2015 – 11/30/2016

Development of Key Components of a [Ga-68]DOTATOC Regulatory Submission and Clinical Adoption.

Role: Co-investigator.

9. Early Phase Clinical Research Support (UCSF)

4/1/2016 – 9/30/2017

Imaging of AR inhibition of second generation AR targeted therapies using PSMA PET.

Role: Principal Investigator.

10. Medical Center Strategic Initiative Funding Program (UCSF)

9/1/2016 – 8/30/2017

Therapeutic PRRT program development.

Role: Principal Investigator.

11. Resource Allocation Program (UCSF)

7/1/2015 – 6/30/2017

NaF and Diffusion PET/MRI for the characterization of osseous metastatic disease in prostate cancer patients being treated with Ra-223.

Role: Principal Investigator.

12. Radiological Society of North America

7/1/2015 – 6/30/2016

Interim response to Y-90 therapy of neuroendocrine tumor using DOTA-TOC PET/MRI.

Role: Principal Investigator.

13. Bayer Healthcare.

9/21/2009 – 12/31/2015.

Comparison of Gadoxetate Disodium Enhanced MRI and Multiphasic CT for the Detection of Hepatocellular Carcinoma. (\$90,000).

Role: Co-investigator.

14. Society of Abdominal Radiology

3/15/2014 – 3/14/2016

Utility of combined Ga-68 DOTA-TATE PET and Eovist MRI utilizing PET/MR.

Role: Principal investigator.

15. GEMS-CTSI fellowship.

7/1/2014 – 6/30/2015

Accelerated UTE/ZTE pulse sequence for the evaluation of pulmonary nodules in the setting of a MR/PET workflow.

Role: Faculty mentor.

16. UCSF Departmental Seed Grant.

Academic year 2008.

The Interaction of Erythropoietin, Intravenous Iron and Gadolinium Chelates in the Development of Nephrogenic Systemic Fibrosis – a Rat Model.

Role: Principle Investigator.

17. UCSF Departmental Seed Grant.

Academic year 2010.

Evaluation of the selective vasoactive effects of vasopressin on hepatic and splanchnic blood flow.

Role: Co-investigator.

18. RSNA Presidents Circle Research Resident Grant.

#RR1006, 7/1/2010 – 6/30/2012.

Validation of an NSF Model in Renal Failure Rats and Evaluation of Imatinib as a Potential Treatment.

Role: Principle Investigator.

19. Microsoft Digital Inclusion grant.

Academic year 2005 – 2006

Smartphone Health Information and Epidemiology Network (SHIEN) – Vietnam.

Role: Software Engineer.

BOOKS

Iagaru A, Hope TA, Veit-Haibach P. (2018) *PET/MRI in Oncology: current and clinical applications*. Springer.

PEER REVIEWED PUBLICATIONS

1. Bammer R, Hope TA, Aksoy M, Alley MT. Time-resolved 3D quantitative flow MRI of the major intracranial vessels: initial experience and comparative evaluation at 1.5T and 3.0T in combination with parallel imaging. *Magn Reson Med*. 2007 Jan;57(1):127-40.
2. Hope TA, Markl M, Wigstrom L, Alley MT, Miller DC, Herfkens RJ. Comparison of flow patterns in ascending aortic aneurysms and volunteers using four-dimensional magnetic resonance velocity mapping. *J Magn Reson Imaging*. 2007 Dec;26(6):1471-9.
3. Hope MD, Meadows AK, Hope TA, Ordovas KG, Reddy GP, Alley MT, Higgins CB. Images in cardiovascular medicine. Evaluation of bicuspid aortic valve and aortic coarctation with 4D flow magnetic resonance imaging. *Circulation*. 2008 May 27;117(21):2818-9.
4. Hope TA, Zarins CK, Herfkens RJ. Initial experience characterizing a type I endoleak from velocity profiles using time-resolved three-dimensional phase-contrast MRI. *J Vasc Surg*. 2009 Jun;49(6):1580-4.
5. Hope MD, Purcell DD, Hope TA, von Morze C, Vigneron DB, Alley MT, Dillon WP. Complete intracranial arterial and venous blood flow evaluation with 4D flow MR imaging. *AJNR*. 2009 Feb;30(2):362-6.
6. Cebal JR, Putman CM, Alley MT, Hope T, Bammer R, Calamante F. Hemodynamics in Normal Cerebral Arteries: Qualitative Comparison of 4D Phase-Contrast Magnetic Resonance and Image-Based Computational Fluid Dynamics. *J Eng Math*. 2009 Aug 1;64(4):367-378.
7. Hope TA, Herfkens RJ, Denianke KS, Leboit PE, Hung YY, Weil E. Nephrogenic Systemic Fibrosis in Patients With Chronic Kidney Disease Who Received Gadopentetate Dimeglumine. *Invest Radiol*. 2009 Mar;44(3):135-139.
8. Hope TA, High WA, LeBoit PE, Chaopathomkul B, Rogut VS, Herfkens RJ, Brasch RC. Nephrogenic Systemic Fibrosis in Rats treated with Erythropoietin and Intravenous Iron. *Radiology*. 2009 Nov;253(2):390-8.
9. Hope MD, Meadows AK, Hope TA, Ordovas KG, Saloner D, Reddy GP, Alley MT, Higgins CB. Clinical evaluation of aortic coarctation with 4D flow MR imaging. *J Magn Reson Imaging*. 2010 Mar;31(3):711-8.

10. Hope MD, Hope TA, Meadows AK, Ordovas KG, Urbania TH, Alley MT, Higgins CB. Bicuspid aortic valve: four-dimensional MR evaluation of ascending aortic systolic flow patterns. *Radiology*. 2010 Apr;255(1):53-61.
11. Hope MD, Hope TA, Urbania TH, Higgins CB. Four-dimensional flow magnetic resonance imaging with wall shear stress analysis before and after repair of aortopulmonary fistula. *Circ Cardiovasc Imaging*. 2010 Nov 1;3(6):766-8.
12. Hope TA, Hope MD, Purcell DD, von Morze C, Vigneron DB, Alley MT, Dillon WP. Evaluation of intracranial stenoses and aneurysms with accelerated 4D flow. *Magn Reson Imaging*. 2010 Jan;28(1):41-6.
13. McGowan PO, Hope TA, Meck WH, Kelsoe G, Williams CL. Impaired social recognition memory in recombination activating gene 1-deficient mice. *Brain Res*. 2011 Apr 6;1383:187-95.
14. Hope MD, Hope TA, Crook SE, Ordovas KG, Urbania TH, Alley MT, Higgins CB. 4D Flow CMR in Assessment of Valve-Related Ascending Aortic Disease. *JACC Imaging*. 2011 Jul;4(7):781-787.
15. Hope TA, Doherty A, Fu Y, Aslam R, Qayyum A, Brasch RC. Evaluation of gadolinium accumulation and fibrosis within the liver after the administration of gadoxetate disodium in a rat model of active hepatic fibrosis. *Radiology*. 2012 Aug;264(2):423-7.
16. Hope TA, LeBoit PE, High WA, Fu Y, Brasch RC. Evaluation of Imatinib Mesylate as a Possible Treatment for Nephrogenic Systemic Fibrosis in a Rat Model. *Magn Reson Imaging*. 2012 Aug 13.
17. Durack JC, Hope TA, Seo Y, Saeed M, He J, Wilson MW, Kerlan RK Jr, Ring EJ. Intravenous Vasopressin for the Prevention of Nontarget Gastrointestinal Embolization during Liver-directed Cancer Treatment: Experimental Study in a Porcine Model. *J Vasc Interv Radiol*. 2012 Nov;23(11):1505-12.
18. Hope TA, Kvitting JP, Hope MD, Miller DC, Markl M, Herfkens RJ. Evaluation of Marfan patients status post valve-sparing aortic root replacement with 4D flow. *Magn Reson Imaging*. 2013 Nov;31(9):1479-84.
19. Hope TA, Saranathan M, Petkovska I, Hargreaves BA, Herfkens RJ, Vasanawala SS. Improvement of gadoxetate arterial phase capture with a high spatio-temporal resolution multiphase three-dimensional SPGR-dixon sequence. *J Magn Reson Imaging*. 2013 Oct;38(4):938-45.
20. Hope TA, Ohliger MA, Qayyum A. MR imaging of diffuse liver disease: from technique to diagnosis. *Radiol Clin North Am*. 2014 Jul;52(4):709-24.
21. Jacobs MA, Weinstein S, Hope TA, Aslam R, Yee J, Coakley F. Neuroendocrine Tumors: Beyond the Abdomen. *J Comput Assist Tomogr*. 2014 Nov-Dec;38(6):898-914.
22. Hope TA, Fowler KJ, Sirlin CB, Costa EA, Yee J, Yeh BM, Heiken JP. Hepatobiliary agents and their role in LI-RADS. *Abdom Imaging*. 2015 Mar;40(3):613-25.
23. Hope TA, Aggarwal R, Simko JP, VanBrocklin HF, Ryan CJ. Somatostatin Imaging of Neuroendocrine-Differentiated Prostate Cancer. *Clin Nucl Med*. 2015 Jun;40(6):540-1.
24. Weinstein S, Mabray MC, Aslam R, Hope T, Yee J, Owens C. Intraoperative sonography during carotid endarterectomy: normal appearance and spectrum of complications. *J Ultrasound Med*. 2015 May;34(5):885-94.
25. Hope TA, Hernandez-Pampaloni H, Nakakura E, VanBrocklin H, Slater J, Jivan S, Aparici CM, Yee J, Bergsland E. Simultaneous 68Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. *Abdominal Imaging*. 2015 Aug;40(6):1432-40.
26. Stephens EH, Hope TA, Kari FA, Escobar Kvitting JP, Liang DH, Herfkens RJ, Miller DC. Greater Asymmetric Wall Shear Stress in Sievers' Type 1/L-R Compared to 0/LAT Bicuspid Aortic Valves after Valve-Sparing Aortic Root Replacement. *J Thorac Cardiovasc Surg*. 2015 Jul;150(1):59-68. doi: 10.1016/j.jtcvs.2015.04.020.

27. Kim SY, Park SH, Wu EH, Wang ZJ, Hope TA, Chang WC, Yeh BM. Transient respiratory motion artifact during arterial phase MRI with gadoxetate disodium: risk factor analyses. *AJR Am J Roentgenol*. 2015 Jun;204(6):1220-7.
28. Burris NS, Johnson KM, Larson PE, Hope MD, Nagle SK, Behr SC, Hope TA. Detection of Small Pulmonary Nodules with Ultrashort Echo Time Sequences in Oncology Patients by Using a PET/MR System. *Radiology*. 2016 Jan;278(1):239-46.
29. Hope MD, Hope TA, Zhu C, Faraji F, Haraldsson H, Ordovas KG, Saloner D. Vascular Imaging With Ferumoxytol as a Contrast Agent. *Am J Roentgenol*. 2015 Jun 23;W1-W8.
30. Hope TA, Petkovska I, Saranathan M, Hargreaves BA, Vasanawala SS. Combined parenchymal and vascular imaging: high spatiotemporal resolution arterial evaluation of hepatocellular carcinoma. *J Magn Reson Imaging*. 2016 Apr;43(4):859-65.
31. Hope TA, Verdin EJ, Bergsland EK, Ohliger MA, Corvera CU, Nakakura EK. Correcting for respiratory motion in liver PET/MRI: preliminary evaluation of the utility of bellows and navigated hepatobiliary phase imaging. *EJNMMI Physics*. 2015;2(1):21.
32. Ehman EC, Behr SC, Umetsu SE, Fidelman N, Yeh BM, Ferrel LD, Hope TA. Rate of observation and inter-observer agreement for LI-RADS major features at CT and MRI in 184 pathology proven hepatocellular carcinomas. *Abdominal Imaging*. 2016 May;41(5):963-9.
33. Kim SY, Wu EH, Park SH, Wang ZJ, Hope TA, Yee J, Zhao LQ, Chang WC, Yeh BM. Comparison of Hepatocellular Carcinoma Conspicuity on Hepatobiliary Phase Images with Gadoxetate Disodium versus Delayed Phase Images with Extracellular Cellular Contrast Agent. *Abdom Radiol (NY)*. 2016 Aug;41(8):1522-31.
34. Vasanawala SS, Nguyen KL, Hope MD, Bridges MD, Hope TA, Reeder SB, Bashir MR. Safety and technique of ferumoxytol administration for MRI. *Magn Reson Med*. 2016 May;75(5):2107-11.
35. Hicks RM, Yee J, Ohliger MA, Weinstein S, Kao J, Ikram NS, Hope TA. Comparison of diffusion-weighted imaging and T2-weighted single shot fast spin-echo: Implications for LI-RADS characterization of hepatocellular carcinoma. *Magn Reson Imaging*. 2016 Apr 21;34(7):915-921.
36. Becker-Weidman DJ, Hope TA, Doshi PH, Patel A, Mitchell DG. Transient washout of hepatic hemangiomas: Potential pitfall mimicking malignancy. *Radiol Case Rep*. 2016 Apr 6;11(2):62-6.
37. Afshar-Oromieh A, Hetzheim H, Kübler W, Kratochwil C, Giesel FL, Hope TA, Eder M, Eisenhut M, Kopka K, Haberkorn U. Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. *Eur J Nucl Med Mol Imaging*. 2016 Aug;43(9):1611-20.
38. Kluijfhout WP, Venkatesh S, Beninato T, Vriens MR, Duh QY, Wilson DM, Hope TA, Suh I. Performance of magnetic resonance imaging in the evaluation of first-time and reoperative primary hyperparathyroidism. *Surgery*. 2016 Jun 15. pii: S0039-6060(16)30129-5.
39. Hope TA, Pampaloni MH, Flavell RR, Nakakura EK, Bergsland EK. Somatostatin receptor PET/MRI for the evaluation of neuroendocrine tumors. *Clinical and Translational Imaging*. 2016;;1-7.
40. Ehman EC, Umetsu SE, Ohliger MA, Fidelman N, Ferrell LD, Yeh BM, Yee J, Hope TA. Imaging prediction of residual hepatocellular carcinoma after locoregional therapy in patients undergoing liver transplantation or partial hepatectomy. *Abdom Radiol (NY)*. 2016 Nov;41(11):2161-2168.
41. Hope TA, Truillet CC, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, Carroll PR, Small EJ, Evans MJ. Imaging Response to Androgen Receptor Inhibition Using 68Ga-PSMA-11 PET: First Human Experience. *J Nucl Med*. 2016 Sep 22.

42. Hope TA, Aslam R, Weinstein S, Yeh BM, Corvera CU, Monto A, Yee J. Change in Liver Imaging Reporting and Data System Characterization of Focal Liver Lesions Using Gadoxetate Disodium Magnetic Resonance Imaging Compared With Contrast-Enhanced Computed Tomography. *J Comput Assist Tomogr*. 2018 May;59(5):852-858.
43. Ikram NS, Yee J, Weinstein S, Yeh BM, Corvera CU, Monto A, Hope TA. Multiple arterial phase MRI of arterial hypervascular hepatic lesions: improved arterial phase capture and lesion enhancement. *Abdom Radiol (NY)*. 2016 Oct 21.
44. Yang J, Khalighi M, Hope TA, Ordovas K, Seo Y. Technical Note: Fast respiratory motion estimation using sorted singles without unlist processing: A feasibility study. *Med Phys*. 2017.
45. Leynes AP, Yang J, Shanbhag DD, Kaushik SS, Seo Y, Hope TA, Wiesinger F, Larson PE. Hybrid ZTE/Dixon MR-based Attenuation Correction for Quantitative Uptake Estimation of Pelvic Lesions in PET/MRI. *Med Phys*. 2017.
46. Kluijfhout WP, Pasternak JD, Gosnell JE, Shen WT, Duh QY, Vriens MR, de Keizer B, Hope TA, Glastonbury CM, Pampaloni MH, Suh I. 18F Fluorocholine PET/MR Imaging in Patients with Primary Hyperparathyroidism and Inconclusive Conventional Imaging: A Prospective Pilot Study. *Radiology*. 2017 Jan 25:160768.
47. Lawhn-Heath C, Flavell RR, Glastonbury C, Hope TA, Behr SC. Incidental Detection of Head and Neck Squamous Cell Carcinoma on 68Ga-PSMA-11 PET/CT. *Clin Nucl Med*. 2017 Feb 3.
48. Kluijfhout WP, Pasternak JD, Beninato T, Drake FT, Gosnell JE, Shen WT, Duh QY, Allen IE, Vriens MR, de Keizer B, Hope TA, Suh I. Diagnostic performance of computed tomography for parathyroid adenoma localization; a systematic review and meta-analysis. *Eur J Radiol*. 2017 Mar;88:117-128.
49. Yang J, Yiqiang J, Jenkins N, Behr SC, Hope TA, Larson PEZ, Vigneron D, Seo Y. Quantitative evaluation of atlas-based attenuation correction for Brain PET in an integrated Time-of-Flight PET/MR imaging system. *Radiology*. 2017.
50. Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, Giesel F, Haberkorn U, Hope TA, Kopka K, Krause BJ, Mottaghy FM, Schöder H, Sunderland J, Wan S, Wester HJ, Fanti S, Herrmann K. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. *Eur J Nucl Med Mol Imaging*. 2017 Mar 10.
51. Fendler WP, Calais J, Allen-Auerbach M, Bluemel C, Eberhardt N, Emmett L, Gupta P, Hartenbach M, Hope TA, Okamoto S, Pfof CH, Pöppel TD, Rischpler C, Schwarzenböck S, Stebner V, Unterrainer M, Zacho HD, Maurer T, Gratzke C, Crispin A, Czernin J, Herrmann K, Eiber M. 68Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study. *J Nucl Med*. 2017 Apr 13.
52. Yang J, Wiesinger F, Kaushik S, Shanbhag D, Hope TA, Larson PEZ, Seo Y. Evaluation of sinus/edge corrected ZTE-based attenuation correction in brain PET/MRI. *J Nucl Med*. 2017 Nov;58(11):1873-1879.
53. Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg M, Feng F, Chang A, Ryan CJ, Small EJ, Carroll PR. Impact of Ga-68 PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. *J Nucl Med*. 2017 Dec;58(12):1956-1961.
54. Fowler KJ, Potretzke TA, Hope TA, Costa EA, Wilson SR. LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma. *Abdom Radiol (NY)*. 2018 Jan;43(1):149-157.
55. Hicks RM, Loening AM, Ohliger MA, Vasanawala SS, Hope TA. Variable refocusing flip angle single-shot fast spin echo imaging of liver lesions: increased speed and lesion contrast. *Abdom Radiol (NY)*. 2017 Mar;43(3):593-599.
56. Lake ST, Greene KL, Westphalen AC, Behr SC, Zagoria R, Small EJ, Carroll PR, Hope TA. Optimal MRI

sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer. *EJNMMI Res.* 2017 Sep 19;7(1):77.

57. Lee JY, Huo EJ, Weinstein S, Santos C, Monto A, Corvera CU, Yee J, Hope TA. Evaluation of an abbreviated screening MRI protocol for patients at risk for hepatocellular carcinoma. *Abdom Radiol (NY)*. 2018 Jul;43(7):1627-1633.
58. Jiang W, Ong F, Johnson KM, Nagle SK, Hope TA, Lustig M, Larson PEZ. Motion robust high resolution 3D free-breathing pulmonary MRI using dynamic 3D image self-navigator. *Magn Reson Med*. 2018 Jun;79(6):2954-2967.
59. Hope TA, Bergsland E, Bozkurt MF, Graham MM, Heaney AP, Herrmann K, Howe JR, Kulke MH, Kunz PL, Mailman J, May L, Metz DC, Millo C, O'Dorisio S, Reidy-Lagunes DL, Soulen MC, Strosberg JR. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. *J Nucl Med*. 2018 Jan;59(1):66-74.
60. Kambadakone AR, Fung A, Gupta RT, Hope TA, Fowler KJ, Lyshchik A, Ganesan K, Yaghmai V, Guimaraes AR, Sahani DV, Miller FH. LI-RADS technical requirements for CT, MRI, and contrast-enhanced ultrasound. *Abdom Radiol (NY)*. 2018 Jan;43(1):56-74.
61. Fowler KJ, Potretzke TA, Hope TA, Costa EA, Wilson SR. LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma. *Abdom Radiol (NY)*. 2018 Jan;43(1):149-157.
62. Leynes AP, Yang J, Wiesinger F, Kaushik SS, Shanbhag DD, Seo Y, Hope TA, Larson PEZ. Direct PseudoCT Generation for Pelvis PET/MRI Attenuation Correction using Deep Convolutional Neural Networks with Multiparametric MRI: Zero Echo-time and Dixon Deep pseudoCT (ZeDD-CT). *J Nucl Med*. 2018.
63. Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, Hope TA, Reiter R, Maurer T, Weber WA, Fendler WP. PROstate cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. *J Nucl Med*. 2017 Mar;59(3):469-478.
64. Wiesinger F, Bylund M, Yang J, Kaushik S, Shanbhag D, Ahn S, Jonsson JH, Lundman JA, Hope T, Nyholm T, Larson P, Cozzini C. Zero TE-based pseudo-CT image conversion in the head and its application in PET/MR attenuation correction and MR-guided radiation therapy planning. *Magn Reson Med*. 2018 Oct;80(4):1440-1451.
65. Wangerin KA, Baratto L, Khalighi MM, Hope TA, Gulaka PK, Deller TW, Iagaru AH. Clinical Evaluation of 68Ga-PSMA-II and 68Ga-RM2 PET Images Reconstructed With an Improved Scatter Correction Algorithm. *AJR Am J Roentgenol*. 2018 Sep;211(3):655-660.
66. Afshar-Oromieh A, Debus N, Uhrig M, Hope TA, Evans MJ, Holland-Letz T, Giesel FL, Kopka K, Hadaschik B, Kratochwil C, Haberkorn U. Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. *Eur J Nucl Med Mol Imaging*. 2018 Jul 7
67. Bailey JJ, Jordan EJ, Burke C, Ohliger MA, Wang ZJ, Loon KV, Varma MG, Hope TA. Does Extended PET Acquisition in PET/MRI Rectal Cancer Staging Improve Results? *AJR Am J Roentgenol*. 2018 Aug 14:1-5.
68. Yang J, Liu J, Wiesinger F, Menini A, Zhu X, Hope TA, Seo Y, Larson PEZ. Developing an efficient phase-matched attenuation correction method for quiescent period PET in abdominal PET/MRI. *Phys Med Biol*. 2018 Sep 10;63(18):185002.
69. Hicks RM, Simko JP, Westphalen AC, Nguyen HG, Greene KL, Zhang L, Carroll PR, Hope TA. Diagnostic Accuracy of 68Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer. *Radiology*. 2018 Sep 18:180788.
70. Polverari G, Ceci F, Allen-Auerbach M, Gupta P, Fishbein MC, Reiter RE, Lee JM, Hope TA, Carroll RM, Czernin J, Calais J. Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by 68Ga-PSMA-11

71. Behr SC, Aggarwal R, VanBrocklin HF, Flavell RR, Gao K, Small EJ, Blecha J, Jivan S, Hope TA, Simko JP, Kurhanewicz J, Noworolski SM, Korn NJ, De Los Santos R, Cooperberg MR, Carroll PR, Nguyen HG, Greene KL, Lanton-Webster B, Berkman CE, Seo Y. First-in-Human Phase I study of CTT1057, a Novel 18F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer. J Nucl Med. 2018.
72. Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll PR, Cooperberg M, Evans MJ, Hope TA. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. Eur Urol Oncol. 2018 May;1(1):78-82.
73. Perez PM, Hope TA, Behr SC, van Zante A, Small EJ, Flavell RR. Intertumoral Heterogeneity of 18F-FDG and 68Ga-PSMA Uptake in Prostate Cancer Pulmonary Metastases. Clinical Nuclear Medicine. 2018.
74. Hope TA, Goodman JZ, Allen IE, Calais J, Fendler WP, Carroll PR. Meta-analysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology. J Nucl Med. 2018 Dec 7.
75. Wu SY, Boreta L, Shinohara K, Nguyen H, Gottschalk AR, Hsu IC, Roach III M, Westphalen AC, Feng FY, Carroll PR, Chang AJ, Hope TA. Impact of staging 68Ga-PSMA-11 PET scans on radiation treatment plans in patients with prostate cancer. Urology. 2018 Dec 20.
76. Xu MJ, Kornberg Z, Gadzinski AJ, Diao D, Cowan JE, Wu SY, Boreta L, Spratt DE, Behr SC, Nguyen HG, Cooperberg MR, Davicioni E, Roach M, Hope TA, Carroll PR, Feng FY. Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer. European Urology Oncology. 2019 Jan 15.
77. Kim S, Dillon WP, Hope TA, El-Sayed IH, van Zante A, Wu K, Masharani U. Ectopic thyroid-stimulating hormone-secreting pituitary adenoma of the nasopharynx diagnosed by 68Ga-DOTA-TATE PET/CT. World Neurosurg. 2019 Feb 21.
78. Hope TA, Calais J, Zhang L, Dieckmann W, Millo C. 111In-pentetreotide scintigraphy vs. 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden. J Nucl Med. 2019 Mar 8.
79. Gambhir SS, Shankar LK, Rosenthal E, Warram JM, Ghesani MV, Hope TA, Jacobs PM, Jacobson GB, Wilson T, Siegel BA. Proceedings - Pathways for Successful Translation of New Imaging Agents and Modalities: Phase III Studies. J Nucl Med. 2019 Mar 8.
80. Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019 Mar 28.
81. Boreta L, Gadzinski AJ, Wu SY, Xu M, Greene K, Quanstrom K, Nguyen HG, Carroll PR, Hope TA, Feng FY. Location of recurrence by Gallium-68 PSMA-11 PET scan in prostate cancer patients eligible for salvage radiotherapy. Urology. 2019 Mar 27.
82. Horvat N, Hope TA, Pickhardt PJ, Petkovska I. Mucinous rectal cancer: concepts and imaging challenges. Abdom Radiol (NY). 2019 Apr 16.
83. Lawhn-Heath C, Flavell RR, Behr SC, Yohannan T, Greene KL, Feng F, Carroll PR, Hope TA. Single-Center Prospective Evaluation of 68Ga-PSMA-11 PET in Biochemical Recurrence of Prostate Cancer. AJR Am J Roentgenol. 2019 Apr 30:1-8.
84. Hope TA, Abbott A, Colucci K, Bushnell DL, Gardner L, Graham WS, Lindsay S, Metz DC, Pryma DA, Stabin MG, Strosberg JR. NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. J Nucl Med. 2019 Jul;60(7):937-943.

85. Chan H, Moseley C, Zhang L, Bergsland EK, H Pampaloni M, Van Loon K, Hope TA. Correlation of DOTATOC Uptake and Pathologic Grade in Neuroendocrine Tumors. *Pancreas*. 2019 Jul 1.
86. Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. *Lancet Oncol*. 2019 Aug;2045(19):30415-2.
87. Silverstein J, Kidder W, Fisher SJ, Hope TA, Maisel S, Ng D, Van Ziffle J, Atreya CE, Van Loon K. Hormone receptor expression of colorectal cancer diagnosed during the peri-partum period. *Endocrine Connections*. 2019.
88. Hope TA, Gollub MJ, Arya S, Bates DDB, Ganeshan D, Harisinghani M, Jhaveri KS, Kassam Z, Kim DH, Korngold E, Lalwani N, Moreno CC, Nougaret S, Paroder V, Paspulati RM, Golia Pernicka JS, Petkovska I, Pickhardt PJ, Rauch GM, Rosenthal MH, Sheedy SP, Horvat N. Rectal cancer lexicon: consensus statement from the society of abdominal radiology rectal & anal cancer disease-focused panel. *Abdom Radiol (NY)*. 2019 Aug 6.
89. Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen W, Rahbar K, Schöder H, Virgolini I, Wester HJ, Bodei L, Fanti S, Haberkorn U, Herrmann K. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). *Eur J Nucl Med Mol Imaging*. 2019 Aug 22.
90. Savoie MB, Laffan A, Brickman C, Daniels B, Levin A, Rowen T, Smith J, Van Blarigan EL, Hope TA, Berry-Lawhorn JM, Anwar M, Van Loon K. A multi-disciplinary model of survivorship care following definitive chemoradiation for anal cancer. *BMC Cancer*. 2019 Sep 11;19(1):906.
91. Rauscher I, Fendler WP, Hope T, Quon A, Nekolla SG, Calais J, Richter A, Haller B, Herrmann K, Weber WA, Czernin J, Eiber M. Can the injected dose be reduced in 68Ga-PSMA-11 PET/CT maintaining high image quality for lesion detection? *J Nucl Med*. 2019 Jul 19.
92. Kasai Y, Mahuron K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK. Prognostic impact of a large mesenteric mass >2 cm in ileal neuroendocrine tumors. *J Surg Oncol*. 2019 Oct 15;10.1002/jso.25727.
93. Fendler WP, Weber M, Irvani A, Hofman MS, Calais J, Czernin J, Ilhan H, Saad F, Small EJ, Smith MR, Perez PM, Hope TA, Rauscher I, Londhe A, Lopez-Gitlitz A, Cheng S, Maurer T, Herrmann K, Eiber M, Hadaschik B. Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. *Clin Cancer Res*. 2019 Sep 11;10.1158/1078-0432.CCR-19-1050.
94. Kasai Y, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Harun N, Kim MO, Warren RS, Bergsland EK, Nakakura EK. Residual tumor volume discriminates prognosis after surgery for neuroendocrine liver metastasis. *J Surg Oncol*. 2019 Dec 11.
95. Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA, Minter RM, Lairmore TC, Tseng JF, Zeh HJ, Libutti SK, Singh G, Lee JE, Hope TA, Kim MK, Menda Y, Halfdanarson TR, Chan JA, Pommier RF. The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. *Pancreas*. 2020 Jan;49(1):1-33.
96. Hope TA, Bodei L, Chan JA, El-Haddad G, Fidelman N, Kunz PL, Mailman J, Menda Y, Metz DC, Mittra ES, Pryma DA, Reidy-Lagunes DL, Singh S, Strosberg JR. NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy. *J Nucl Med*. 2020 Feb;61(2):222-227.
97. Chandramohan D, Cao P, Han M, An H, Sunderland JJ, Kinahan PE, Laforest R, Hope TA, Larson PEZ. Bone

98. Trabulsi EJ, Rumble RB, Jadvar H, Hope T, Pomper M, Turkbey B, Rosenkrantz AB, Verma S, Margolis DJ, Froemming A, Oto A, Purysko A, Milowsky MI, Schlemmer HP, Eiber M, Morris MJ, Choyke PL, Padhani A, Oldan J, Fanti S, Jain S, Pinto PA, Keegan KA, Porter CR, Coleman JA, Bauman GS, Jani AB, Kamradt JM, Sholes W, Vargas HA. Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. *J Clin Oncol*. 2020 Jan 15;JCO1902757.
99. Jadvar H, Ballas LK, Choyke PL, Fanti S, Gulley JL, Herrmann K, Hope TA, Klitzke AK, Oldan JD, Pomper MG, Rowe SP, Subramaniam RM, Taneja SS, Vargas HA, Ahuja S. Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment. *J Nucl Med*. 2020 Apr;61(4):552-562.
100. Lawhn-Heath C, Fidelman N, Chee B, Jivan S, Armstrong E, Zhang L, Lindsay S, Bergsland EK, Hope TA. Intra-arterial Peptide Receptor Radionuclide Therapy using 90Y DOTATOC for Hepatic Metastases of Neuroendocrine Tumors. *J Nucl Med*. 2020 Jun 8.
101. Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, O'Dorisio TM, Halperin DM, Fishbein L, Eads J, Hope TA, Singh S, Salem R, Metz DC, Naraev BG, Reidy-Lagunes DL, Howe JR, Pommier RF, Menda Y, Chan JA. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. *Pancreas*. 2020 Aug;49(7):863-881.
102. Singh S, Bergsland EK, Card CM, Hope TA, Kunz PL, Laidley DT, Lawrence B, Leyden S, Metz DC, Michael M, Modahl LE, Myrehaug S, Padda SK, Pommier RF, Ramirez RA, Soulen M, Strosberg J, Sung A, Thawer A, Wei B, Xu B, Segelov E. CommNETs/NANETS guidelines for the diagnosis and management of patients with Lung Neuroendocrine Tumors: An international collaborative endorsement and update of the 2015 ENETS expert consensus guidelines. *J Thorac Oncol*. 2020 Jul 11:S1556-0864(20)30548-7.
103. Fendler WP, Calais J, Eiber M, Simko JP, Kurhanewicz J, Santos RD, Feng FY, Reiter RE, Rettig MB, Nickols NG, Kishan AU; PSMA PET Reader Group, Slavik R, Carroll PR, Lawhn-Heath C, Herrmann K, Czernin J, Hope TA. False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial. *Eur J Nucl Med Mol Imaging*. 2020 Aug 17.
104. Murthy V, Smith RL, Tao DH, Lawhn-Heath CA, Korenchan DE, Larson PEZ, Flavell RR, Hope TA. 68Ga-PSMA-11 PET/MRI: determining ideal acquisition times to reduce noise and increase image quality. *EJNMMI Phys*. 2020 Aug 26;7(1):54.
105. Hall WA, Paulson E, Davis BJ, Spratt DE, Morgan TM, Dearnaley D, Tree AC, Efsthathiou JA, Harisinghani M, Jani AB, Buyyounouski MK, Pisansky TM, Tran PT, Karnes RJ, Chen RC, Cury FL, Michalski JM, Rosenthal SA, Koontz BF, Wong AC, Nguyen P, Hope TA, Feng F, Sandler HM, Lawton CA. NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Post-Operative Prostate Cancer. *Int J Radiat Oncol Biol Phys*. 2020 Aug 27:S0360-3016(20)34124-9.
106. Bucknor MD, Lichtensztajn DY, Lin TK, Borno HT, Gomez SL, Hope TA. Disparities in PET imaging for prostate cancer at a tertiary academic medical center. *J Nucl Med*. 2020 Sep 25.
107. Johnson RD, Bath NK, Rinker J, Fong S, St James S, Pampaloni MH, Hope TA. Introduction to the D-SPECT for Technologists: Workflow Using a Dedicated Digital Cardiac Camera. *J Nucl Med Technol*. 2020 Oct 5;jnmt.120.254870.
108. Lawhn-Heath C, Yom SS, Liu C, Villanueva-Meyer JE, Aslam M, Smith R, Narwal M, Juarez R, Behr SC, Pampaloni MH, Chan JW, Glastonbury CM, Hope TA, Flavell RR. Gallium-68 prostate-specific membrane antigen ([68Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study. *EJNMMI Res*. 2020 Oct 22;10(1):128.
109. Borno HT, Kuo Lin T, Odisho AY, Desai A, Koshkin V, Werner K, Legaspi N, Bucknor M, Bell A, Zhang S,

Hope TA. Evaluating determinants of receipt of molecular imaging in biochemical recurrent prostate cancer. *Cancer Med.* 2020 Nov 28.

110. Calais J, Armstrong WR, Kishan AU, Booker KM, Hope TA, Fendler WP, Elashoff D, Nickols NG, Czernin J. Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome. *Eur Urol Focus.* 2020 Dec 29:S2405-4569(20)30311-4.
111. Whitman J, Allen IE, Bergsland EK, Suh IA, Hope TA. Assessment and comparison of fluorocholine PET and sestamibi scans in identifying parathyroid adenomas: a meta-analysis. *J Nucl Med.* 2021 Jan 15
112. Tranel J, Feng FY, St James ST, Hope TA. Effect of microdistribution of alpha and beta-emitters in targeted radionuclide therapies on delivered absorbed dose in a GATE model of bone marrow. *Phys Med Biol.* 2020 Dec 15.
113. Susko MS, Lazar AA, Wang CJ, Van Loon K, Feng M, Hope TA, Behr S, Anwar M. Use of advanced PET-volume metrics predicts risk of local recurrence and overall survival in anal cancer. *PLoS One.* 2021 Feb 4;16(2):e0246535.
114. Ceci F, Oprea-Lager DE, Emmett L, Adam JA, Bomanji J, Czernin J, Eiber M, Haberkorn U, Hofman MS, Hope TA, Kumar R, Rowe SP, Schwarzenboeck SM, Fanti S, Herrmann K. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. *Eur J Nucl Med Mol Imaging.* 2021 Feb 19.
115. Hope TA, Graces C, Calais J, Ehman E, Johnson GB, Thompson D, Aslam M, Duh QY, Gosnell J, Shen W, Roman S, Sosa JA, Kluijfhout W, Seib CS, Villanueva-Meyer J, Pampaloni MH, Suh I. Accuracy of 18F-fluorocholine PET for the detection of parathyroid adenomas: prospective single center study. *J Nucl Med.* 2021 Mar 5
116. Gong K, Yang J, Larson PEZ, Behr SC, Hope TA, Seo Y, Li Q. MR-based Attenuation Correction for Brain PET Using 3D Cycle-Consistent Adversarial Network. *IEEE Trans Radiat Plasma Med Sci.* 2021 Mar;5(2):185-192.
117. Fishbein L, Del Rivero J, Else T, Howe JR, Asa SL, Cohen DL, Dahia PLM, Fraker DL, Goodman KA, Hope TA, Kunz PL, Perez K, Perrier ND, Pryma DA, Ryder M, Sasson AR, Soulen MC, Jimenez C. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. *Pancreas.* 2021 Apr 1;50(4):469-493.
118. Salavati A, Gencturk M, Koksel Y, Schik AN, Carroll PR, Feng FY, Rowe SP, Lawhn-Heath C, Hope TA, Froelich JW. A bicentric retrospective analysis of clinical utility of 18F-fluciclovine PET in biochemically recurrent prostate cancer following primary radiation therapy: is it helpful in patients with a PSA rise less than the Phoenix criteria? *Eur J Nucl Med Mol Imaging.* 2021 Jun 6.
119. Catana C, Laforest R, An H, Boada F, Cao T, Faul D, Jakoby B, Jansen FP, Kemp BJ, Kinahan PE, Larson PEZ, Levine MA, Maniawski P, Mawlawi O, McConathy J, McMillan A, Price JC, Rajagopal A, Sunderland J, Veit-Haibach P, Wangerin KA, Ying C, Hope TA. A Path to Qualification of PET/MR Scanners for Multicenter Brain Imaging Studies: Evaluation of MR-based Attenuation Correction Methods Using a Patient Phantom. *J Nucl Med.* 2021 Jul 22;jnumed.120.261881. doi: 10.2967/jnumed.120.261881.
120. Graves CE, Hope TA, Kim J, Pampaloni MH, Kluijfhout W, Seib CD, Gosnell JE, Shen WT, Roman SA, Sosa JA, Duh QY, Suh I. Superior sensitivity of 18F-fluorocholine: PET localization in primary hyperparathyroidism. *Surgery.* 2021 Jul 20:S0039-6060(21)00573-0. doi: 10.1016/j.surg.2021.05.056.
121. Abghari-Gerst M, Armstrong WR, Nguyen K, Calais J, Czernin J, Lin D, Jariwala N, Rodnick M, Hope TA, Hearn J, Montgomery JS, Alva A, Reichert ZR, Spratt DE, Johnson TD, Scott PJH, Piert M. A comprehensive assessment of 68Ga-PSMA-11 PET in biochemically recurrent prostate cancer: Results from a prospective multi-center study in 2005 patients. *J Nucl Med.* 2021 Jul 29;jnumed.121.262412. doi: 10.2967/jnumed.121.262412.

122. Yap A, Hope TA, Graves CE, Kluijfhout W, Shen WT, Gosnell JE, Sosa JA, Roman SA, Duh QY, Suh I. A cost-utility analysis of 18F-fluorocholine-positron emission tomography imaging for localizing primary hyperparathyroidism in the United States. *Surgery*. 2021 Jul 31:S0039-6060(21)00651-6. doi: 10.1016/j.surg.2021.03.075.
123. Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, Behr SC, Zhang L, Barbato F, Ceci F, Farolfi A, Schwarzenböck SM, Unterrainer M, Zacho HD, Nguyen HG, Cooperberg MR, Carroll PR, Reiter RE, Holden S, Herrmann K, Zhu S, Fendler WP, Czernin J, Calais J. Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial. *JAMA Oncol*. 2021 Sep 16. doi: 10.1001/jamaoncol.2021.3771.
124. Hamdi M, Natsuaki Y, Wangerin KA, An H, St. James S, Kinahan PE, Sunderland JJ, Larson PEZ, Hope TA, Laforest R. Evaluation of attenuation correction in PET/MRI with synthetic lesion insertion. *J Med Imag*. 2021;8(05). doi: 10.1117/1.JMI.8.5.056001.
125. Rajagopal A, Dwork N, Hope TA, Larson PEZ, "Enhanced PET/MRI reconstruction via dichromatic interpolation of domain- translated zero-dose PET," *Proc. SPIE 11595, Medical Imaging 2021: Physics of Medical Imaging*, 115954B (15 February 2021); doi: 10.1117/12.2580915
126. Jadvar H, Calais J, Fanti S, Feng F, Greene KL, Gulley JL, Hofman M, Koontz BF, Lin DW, Morris MJ, Rowe SP, Royce TJ, Salami S, Savir-Baruch B, Srinivas S, Hope TA. Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. *J Nucl Med*. 2021 Sep 30;jnumed.121.263262.
127. Ferdinandus J, Fendler WP, Farolfi A, Washington S, Mohamad O, Pampaloni MH, Scott PJ, Rodnick M, Viglianti BL, Eiber M, Herrmann K, Czernin J, Armstrong WR, Calais J, Hope TA, Pierr MA. PSMA PET validates higher rates of metastatic disease for European Association of Urology Biochemical Recurrence Risk Groups: an international multicenter study. *J Nucl Med*. 2021 Oct 7;jnumed.121.262821.
128. Laforest R, Khalighi M, Natsuaki Y, Rajagopal A, Chandramohan D, Byrd D, An H, Larson P, James SS, Sunderland JJ, Kinahan PE, Hope TA. Harmonization of PET image reconstruction parameters in simultaneous PET/MRI. *EJNMMI Phys*. 2021 Nov 5;8(1):75.
129. Kasai Y, Masui T, Nakakura EK, Nakano K, Sato A, Uchida Y, Yogo A, Nagai K, Anazawa T, Hope TA, Kim GE, Whitman J, Le BK, Takaori K, Bergsland EK, Hatano E, Uemoto S. Preoperative risk stratification of lymph node metastasis for non-functional pancreatic neuroendocrine neoplasm: An international dual-institutional study. *Pancreatol*. 2021 Oct 28:S1424-3903(21)00608-6.
130. Sun N, Yang Y, Miao H, Redublo P, Liu H, Liu W, Huang YW, Teng PC, Zhang C, Zhang RY, Smalley M, Yang P, Chou SJ, Huai K, Zhang Z, Lee YT, Wang JJ, Wang J, Liang IY, Zhang TX, Zhang D, Liang L, Weiss PS, Posadas EM, Donahue T, Hecht JR, Allen-Auerbach MS, Bergsland EK, Hope TA, Pei R, Zhu Y, Tseng HR, Heaney AP. Discovery and characterization of circulating tumor cell clusters in neuroendocrine tumor patients using nanosubstrate-embedded microchips. *Biosens Bioelectron*. 2021 Dec 3;199:113854.
131. Lawhn-Heath C, Hope TA, Martinez J, Fung EK, Shin J, Seo Y, Flavell RR. Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose. *Lancet Oncol*. 2022 Feb;23(2):e75-e87.
132. Leach JR, Shen H, Huo E, Hope TA, Mitsouras D, Whooley MA, Hope MD. Impact of Implicit Abdominal Aortic Aneurysm Screening in the Veterans Affairs Health Care System Over 10 Years. *J Am Heart Assoc*. 2022 Mar 29:e024571.
133. Emmett LM, Papa N, Buteau J, Ho B, Liu V, Roberts M, Thompson J, Moon D, Sheehan-Dare G, Alghazo O, Agrawal S, Murphy DG, Stricker P, Hope TA, Hofman M. The PRIMARY Score: Using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis. *J Nucl Med*. 2022 Mar 17;jnumed.121.263448.
134. Love C, Desai NB, Abraham T, Banks KP, Bodei L, Boike T, Brown RKJ, Bushnell DL, DeBlanche LE, Dominello MM, Francis T, Grady EC, Hobbs RF, Hope TA, Kempf JS, Pryma DA, Rule W, Savir-Baruch B,

Sethi I, Subramaniam RM, Xiao Y, Schechter NR. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy. *Am J Clin Oncol*. 2022 May 4.

135. Love C, Desai NB, Abraham T, Banks KP, Bodei L, Boike T, Brown RKJ, Bushnell DL, DeBlanche LE, Dominello MM, Francis T, Grady EC, Hobbs RF, Hope TA, Kempf JS, Pryma DA, Rule W, Savir-Baruch B, Sethi I, Subramaniam RM, Xiao Y, Schechter NR. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy. *Clin Nucl Med*. 2022 Jun 1;47(6):503-511.
136. Jha A, Patel M, Carrasquillo JA, Chen CC, Millo CC, Maass-Moreno R, Ling A, Lin FI, Lechan RM, Hope TA, Taieb DA, Civelek AC, Pacak K. Choice is good at times: the emergence of [64Cu]Cu-DOTATATE based somatostatin receptor imaging in the era of [68Ga]Ga-DOTATATE. *J Nucl Med*. 2022 May 26;jnumed.122.264183. PMID: 35618479
137. Leynes AP, Ahn SP, Wangerin KA, et al. Attenuation Coefficient Estimation for PET/MRI With Bayesian Deep Learning pseudo-CT and Maximum Likelihood Estimation of Activity and Attenuation. *IEEE Trans Rad Plasma Med Sciences*. 2022;6:678–689.
138. Kwon DH, Shakhnazaryan N, Shui D, et al. Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers. *Urol Oncol*. 2022.
139. Roberts MJ, Maurer T, Perera M, Eiber M, Hope TA, Ost P, Siva S, Hofman MS, Murphy DG, Emmett L, Fendler WP. Using PSMA imaging for prognostication in localized and advanced prostate cancer. *Nat Rev Urol*. 2022 Dec 6. doi: 10.1038/s41585-022-00670-6.
140. Hope TA, Allen-Auerbach M, Bodei L, Calais J, Dahlbom M, Dunnwald LK, Graham MM, Jacene HA, Heath CL, Mittra ES, Wright CL, Fendler WP, Herrmann K, Taïeb D, Kjaer A. SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors. *J Nucl Med*. 2023 Feb;64(2):204-210. doi: 10.2967/jnumed.122.264860.
141. Konstantinoff KS, Morani AC, Hope TA, Bhosale PR, Francis IR, Yano M, Iravani A, Trikalinos NA, Itani M. Pancreatic neuroendocrine tumors: tailoring imaging to specific clinical scenarios. *Abdom Radiol (NY)*. 2023 Feb 4. doi: 10.1007/s00261-022-03737-5.
142. Golia Pernicka JS, Rauch GM, Gangai N, Bates DDB, Ernst R, Hope TA, Horvat N, Sheedy SP, Gollub MJ. Imaging of Anal Squamous Cell Carcinoma: Survey Results and Expert Opinion from the Rectal and Anal Cancer Disease-Focused Panel of the Society of Abdominal Radiology. *Abdom Radiol (NY)*. 2023 Mar 18.
143. Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, Giesel FL, Reiter R, Maurer T, Heck M, Gafita A, Morris MJ, Fanti S, Weber WA, Hope TA, Hofman MS, Fendler WP, Eiber M. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). *Eur Urol*. 2023 Mar 17:S0302-2838(23)02574-5. doi: 10.1016/j.eururo.2023.02.002.
144. Hotta M, Gafita A, Murthy V, Benz MR, Sonni I, Burger IA, Eiber M, Emmett L, Farolfi A, Fendler WP, Weber MM, Hofman MS, Hope TA, Kratochwil C, Czernin J, Calais J. PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [177Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study. *J Nucl Med*. 2023 Mar 30;jnumed.122.265242. doi: 10.2967/jnumed.122.265242.
145. Wang SJ, Whitman J, Paciorek A, Le BK, Nakakura EK, Behr SC, Joseph N, Zhang L, Hope TA, Bergsland EK. Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time. *J Neuroendocrinol*. 2023 Mar 17:e13260. doi: 10.1111/jne.13260. PMID: 37002881
146. Raj N, Chan JA, Wang SJ, Aggarwal RR, Calabrese S, DeMore A, Fong L, Grabowsky J, Hope TA, Kolli KP, Mulvey CK, Munster PN, Perez K, Punn S, Reidy-Lagunes D, Von Fedak S, Zhang L, Bergsland EK. Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas. *Br J Cancer*. 2023 May 19. doi: 10.1038/s41416-023-02298-8.

147. Mei R, Kessler L, Pabst KM, Weber M, Schimdkonz C, Rischpler C, Zacho HD, Hope T, Schwarzenböck SM, Allen-Auerbach M, Emmett L, Ferdinandus J, Unterrainer M, Schaarschmidt BM, Umutlu L, Farolfi A, Castellucci P, Nanni C, Telo S, Fanti S, Herrmann K, Fendler WP. 68Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study. *J Nucl Med*. 2023 May 25;265245. doi: 10.2967/jnumed.122.265245. Online ahead of print. PMID: 37230530
148. Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, Osborne JR, Iravani A, Koo P, Lindenberg L, Baum RP, Bozkurt MF, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen WJG, Rahbar K, Schoder H, Virgolini I, Bodei L, Fanti S, Haberkorn U, Hermann K. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). *Eur J Nucl Med Mol Imaging*. 2023 May 29. doi: 10.1007/s00259-023-06255-8. PMID: 37246997
149. Hope TA, Antonarakis ES, Bodei L, Calais J, Iravani A, Jacene H, Koo PJ, Morgans AK, Osborne JR, Tagawa ST, Taplin ME, Sartor O, Morris MJ. SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy. *J Nucl Med*. 2023 Sep;64(9):1417-1423. doi: 10.2967/jnumed.123.265952. PMID: 37290800
150. Rajagopal A, Natsuaki Y, Wangerin K, Hamdi M, An H, Sunderland JJ, Laforest R, Kinahan PE, Larson PEZ, Hope TA. Synthetic PET via Domain Translation of 3-D MRI. *IEEE Trans Radiat Plasma Med Sci*. 2023 Apr;7(4):333-343. doi: 10.1109/trpms.2022.3223275. Epub 2022 Nov 18. PMID: 37396797
151. Werner RA, Hartrampf PE, Fendler WP, Serfling SE, Derlin T, Higuchi T, Pienta KJ, Gafita A, Hope TA, Pomper MG, Eiber M, Gorin MA, Rowe SP. Prostate-specific Membrane Antigen Reporting and Data System Version 2.0. *Eur Urol*. 2023 Jul 4:S0302-2838(23)02903-2. doi: 10.1016/j.eururo.2023.06.008.
152. Djaïleb L, Armstrong WR, Thompson D, Gafita A, Farolfi A, Rajagopal A, Grogan TR, Nguyen K, Benz MR, Hotta M, Barbato F, Ceci F, Schwarzenböck SM, Unterrainer M, Zacho HD, Juarez R, Cooperberg M, Carroll P, Washington S, Reiter RE, Eiber M, Herrmann K, Fendler WP, Czernin J, Hope TA, Calais J. Presurgical 68Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial. *Eur Urol*. 2023 Jul 21:S0302-2838(23)02955-X. doi: 10.1016/j.eururo.2023.06.022.
153. Hope TA, Benz M, Jiang F, Thompson D, Barbato F, Juarez R, Hernandez Pampaloni M, Allen-Auerbach M, Gupta P, Fendler WP, Calais J. Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? An International Multicenter Retrospective Study with Masked Independent Readers. *J Nucl Med*. 2023 Aug 17;jnumed.123.265916. doi: 10.2967/jnumed.123.265916. PMID: 37591547
154. Singh S, Hope TA, Bergsland EB, Bodei L, Bushnell DL, Chan JA, Chasen BR, Chauhan A, Das S, Dasari A, Del Rivero J, El-Haddad G, Goodman KA, Halperin DM, Lewis MA, Lindwasser OW, Myrehaug S, Raj NP, Reidy-Lagunes DL, Soares HP, Strosberg JR, Kohn EC, Kunz PL; NET CTPM participants. Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting. *J Natl Cancer Inst*. 2023 Sep 7;115(9):1001-1010. doi: 10.1093/jnci/djad096. PMID: 37255328
155. Lee S, Kassam Z, Baheti AD, Hope TA, Chang KJ, Korngold EK, Taggart MW, Horvat N. Rectal cancer lexicon 2023 revised and updated consensus statement from the Society of Abdominal Radiology Colorectal and Anal Cancer Disease-Focused Panel. *Abdom Radiol (NY)*. 2023 Sep;48(9):2792-2806. doi: 10.1007/s00261-023-03893-2. Epub 2023 May 5. PMID: 37145311
156. Golia Pernicka JS, Rauch GM, Gangai N, Bates DDB, Ernst R, Hope TA, Horvat N, Sheedy SP, Gollub MJ. Imaging of Anal Squamous Cell Carcinoma: Survey Results and Expert Opinion from the Rectal and Anal Cancer Disease-Focused Panel of the Society of Abdominal Radiology. *Abdom Radiol (NY)*. 2023 Sep;48(9):3022-3032. doi: 10.1007/s00261-023-03863-8. Epub 2023 Mar 18. PMID: 36932225
157. Veit-Haibach P, Ahlström H, Boellaard R, Delgado Bolton RC, Hesse S, Hope T, Huellner MW, Iagaru A,

Johnson GB, Kjaer A, Law I, Metser U, Quick HH, Sattler B, Umutlu L, Zaharchuk G, Herrmann K. International EANM-SNMML-ISMRL consensus recommendation for PET/MRI in oncology. *Eur J Nucl Med Mol Imaging*. 2023 Oct;50(12):3513-3537. doi: 10.1007/s00259-023-06406-x. Epub 2023 Aug 25. PMID: 37624384

158. Aggarwal R, Starzinski S, de Kouchkovsky I, Koshkin V, Bose R, Chou J, Desai A, Kwon D, Kaushal S, Trihy L, Rastogi M, Ippisch R, Aslam M, Friedlander T, Feng F, Oh D, Cheung A, Small E, Evans M, Fong L, Hope TA. Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. *Lancet Oncol*. 2023 Nov;24(11):1266-1276. doi: 10.1016/S1470-2045(23)00451-5. PMID: 37922930

NON-PEER REVIEWED PUBLICATIONS AND OTHER CREATIVE ACTIVITIES:

Review Articles and Other Articles

1. Hope TA, Herfkens RJ. Imaging of the Thoracic Aorta with Time-Resolved Three-Dimensional Phase-Contrast MRI: A Review. *Semin Thorac Cardiovasc Surg*. 2008 Winter;20(4):358-64.
2. Hope TA, Hope MD. Improved Risk Assessment for Abdominal Aortic Aneurysm Rupture Off-the-Wall Imaging. *J Am Coll Cardiol*. 2011 Dec 6;58(24):2531-2.
3. Hope MD, Hope TA. Functional and molecular imaging techniques in aortic aneurysm disease. *Curr Opin Cardiol*. 2013 Nov;28(6):609-18.
4. Hope TA, Menda Y. Update on Somatostatin Receptor PET Agents. SNMMI PET Center of Excellence Newsletter. 2015 12(5).
5. Hope TA, Iagaru A. Ga-68 PSMA PET in the United States. SNMMI CTN Pathways. January 2016.
6. Flavell RR, Hope TA. 68Ga-PSMA for Imaging Prostate Cancer. SNMMI CTN Pathways. January 2016.
7. Hope TA, Aggarwal RR, Westphalen AC, Cooperberg MR, Greene KL. Targeted PET imaging for prostate-specific membrane antigen in prostate cancer. *Future Oncol*. 2016 Nov;12(21):2393-2396.
8. Zukotynski K, Jadvar H, Hope TA, Subramaniam RM, Van Loon K, Varma M, Niederkohr RD. SNMMI Comment on the 2016 Society of Surgical Oncology "Choosing Wisely" Recommendation on the Use of PET/CT in Colorectal Cancer. *J Nucl Med*. 2016 Sep 29.
9. Ehman EC, Johnson GB, Villanueva-Meyer JE, Cha S, Leynes AP, Larson PE, Hope TA. PET/MRI: Where might it replace PET/CT? *J Magn Reson Imaging*. 2017 Nov;46(5):1247-1262.
10. Ohliger MA, Hope TA, Chapman JS, Chen LM, Behr SC, Poder L. PET/MR Imaging in Gynecologic Oncology. *Magn Reson Imaging Clin N Am*. 2017 Aug;25(3):667-684.
11. Huo E, Wilson DM, Eisenmenger L, Hope TA. The Role of PET/MR Imaging in Precision Medicine. *PET Clin*. 2017 Oct;12(4):489-501.
12. Fowler KJ, Potretzke TA, Hope TA, Costa EA, Wilson SR, Sirlin CB, Tang A, Kielar A. Letter to the editor response. *Abdom Radiol (NY)*. 2018 Jan;43(1):239.
13. Lehrman ED, Plotnik AN, Hope T, Saloner D. Ferumoxytol-enhanced MRI in the peripheral vasculature. *Clin Radiol*. 2018 May 3.
14. Hope TA, Afshar-Oromieh A, Eiber M, Emmett L, Fendler WP, Lawhn-Heath C, Rowe SP. Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications. *AJR Am J Roentgenol*. 2018 Jun 27:1-9.
15. Fraum TJ, Ludwig DR, Hope TA, Fowler KJ. PET/MRI for Gastrointestinal Imaging: Current Clinical Status and

Future Prospects. *Gastroenterol Clin North Am*. 2018 Sep;47(3):691-714.

16. Fraum TJ, Ludwig DR, Kim EH, Schroeder P, Hope TA, Ippolito JE. Prostate cancer PET tracers: essentials for the urologist. *Can J Urol*. 2018 Aug;25(4):9371-9383.
17. Mallak N, Hope TA, Guimaraes AR. PET/MR Imaging of the Pancreas. *Magn Reson Imaging Clin N Am*. 2018 26(3), 345–362.
18. Miyahira AK, Den RB, Carlo MI, de Leeuw R, Hope TA, Karzai F, McKay RR, Salami SS, Simons JW, Pienta KJ, Soule HR. Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting. *The Prostate*. 2018.
19. Wu SY, Feng FY, Hope TA. AUTHOR REPLY PSMA-PET: a maturing tool. *Urology*. 2018 Dec 20.
20. Hope TA, Fayad ZA, Fowler KJ, Holley D, Iagaru AH, McMillan A, Veit-Haibach P, Witte RJ, Zaharchuk G, Catana C. State of the Art PET/MRI: Applications and Limitations - Summary of the First ISMRM/SNMMI Co-Provided Workshop on PET/MRI. *J Nucl Med*. 2019 May 23.
21. Hope TA. PET/MRI in Prostate Cancer. *SNMMI Correlative Imaging Council Newsletter*. June 2019.
22. Hope TA, Kassam Z, Loening A, McNamara MM, Paspulati R. The use of PET/MRI for imaging rectal cancer. *Abdom Radiol (NY)*. 2019 Jun 14.
23. Boreta L, Gadzinski AJ, Hope TA, Feng FY. Author Reply. *Urology*. 2019 Jul;129:163-164.
24. Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Fendler WP, Czernin J. What is the best PET target for early biochemical recurrence of prostate cancer?-Authors' reply. *Lancet Oncol*. 2019 Nov;20(11):e609-e610.
25. Sunderland JJ, Czernin J, Hope T. A Conversation with John Sunderland, Johannes Czernin, and Thomas Hope. *J Nuc Med*. 2020 Apr;61(4):477-479.
26. Bergsland EK, Halperin DM, Dillon JS, Dasari NA, Kunz PL, Soares HP, Pryma D, Bodei L, Hope T, Soulen MC, Mailman J, Howe JR. North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19. *Pancreas*. 2020 Jul;49(6):723-728.
27. Calais J, Czernin J, Zhu S, Hope T. 68Ga-PSMA-11: Moving Toward Clinical Use. *Pathways: The Clinical Trials Network Newsletter*. June 2020.
28. Bodei L, Bergsland EK, de Herder WK, Ferone D, Hicks RJ, Hope TA, Kunikowska JA, Pavel M, Reidy-Lagunes DL, Siveke J, Strosberg JR, Dittmer U, Herrmann K. Peptide Receptor Radionuclide Therapy (PRRT) during the COVID-19 pandemic: are there any concerns? *J Nucl Med*. 2020 Jun 23;jnumed.120.249136.
29. Panda A, Goenka AH, Hope TA, Veit-Haibach P. PET/Magnetic Resonance Imaging Applications in Abdomen and Pelvis. *Magn Reson Imaging Clin N Am*. 2020 Aug;28(3):369-380.
30. Osborne JR, Hope TA. A Conversation Between Joseph Osborne and Thomas Hope. *J Nucl Med*. 2020 Sep;61(9):1275-1277.
31. Hope TA. Updates to the Appropriate-Use Criteria for Somatostatin Receptor PET. *J Nucl Med*. 2020 Dec;61(12):1764.
32. Hope TA. From Compassionate Use to Phase 3 Trial: The Impact of Germany's PSMA-617 Literature. *J Nucl Med*. 2020 Dec;61(Suppl 2):255S-256S.
33. Sartor O, Hope TA, Calais J, Fendler WP. Oliver Sartor Talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler About FDA Approval of PSMA. *J Nucl Med*. 2021 Feb;62(2):146-148.

34. Murthy V, Sonni I, Jariwala N, Juarez R, Reiter RE, Raman SS, Hope TA. The Role of PSMA PET/CT and PET/MRI in the Initial Staging of Prostate Cancer. *Eur Urol Focus*. 2021 Feb 1:S2405-4569(21)00040-7.
35. Hope TA, Calais J. PSMA-targeted radiopharmaceutical therapy in patients with metastatic castration-resistant prostate cancer. *Lancet*. 2021 Feb 11:S0140-6736(21)00349-4.
36. Jha A, Taieb D, Carrasquillo JA, Pryma DA, Patel M, Millo C, de Herder WW, Del Rivero J, Crona J, Shulkin BL, Virgolini I, Chen AP, Mittal BR, Basu S, Dillon JS, Hope TA, Mari Aparici C, Iagaru A, Hicks RJ, Avram AM, Strosberg JR, Civelek AC, Lin FI, Pandit-Taskar N, Pacak K. High-specific-activity ¹³¹I-MIBG vs ¹⁷⁷Lu-DOTATATE targeted radionuclide therapy for metastatic pheochromocytoma and paraganglioma. *Clin Cancer Res*. 2021 Mar 8.
37. Koontz BF, Hope TA. More Answers and More Questions About Radiotherapy for Metastatic Prostate Cancer. *JAMA Oncol*. 2021 Feb 18.
38. Bucknor MD, Hope TA. Reply: "Disparities in PET imaging for prostate cancer at a tertiary academic medical center". *J Nucl Med*. 2021 Mar 19.
39. Lawhn-Heath C, Salavati A, Behr SC, Rowe SP, Calais J, Fendler WP, Eiber M, Emmett L, Hofman MS, Hope TA. Prostate-specific Membrane Antigen PET in Prostate Cancer. *Radiology*. 2021 Mar 30:202771.
40. Afaq A, Faul D, Chebrolu VV, Wan S, Hope TA, Haibach PV, Bomanji J. Pitfalls on PET/MRI. *Semin Nucl Med*. 2021 May 18:S0001-2998(21)00019-2.
41. Park SY, Parihar AS, Bodei L, Hope TA, Mallak N, Millo C, Prasad K, Wilson D, Zukotynski K, Mittra E. Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects. *J Nucl Med*. 2021 Jul 22:jnumed.120.251512. doi: 10.2967/jnumed.120.251512.
42. Iravani A, Hope TA. RESIST-PC: US Academic Foray into PSMA Theranostic Trials. *J Nucl Med*. 2021 Aug 5:jnumed.121.262602. doi: 10.2967/jnumed.121.262602.
43. Graves CE, Hope TA, Suh I. Response to "Preoperative localization in primary hyperparathyroidism: Views from the developing world". *Surgery*. 2021 Nov 20:S0039-6060(21)01007-2. doi: 10.1016/j.surg.2021.10.032.
44. Sgouros G, Dewaraja YK, Escorcía F, Graves SA, Hope TA, Iravani A, Pandit-Taskar N, Saboury B, James SS, Zanzonico PB. Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns. *J Nucl Med*. 2021 Dec;62(Suppl 3):12S-22S.
45. Pandit-Taskar N, Iravani A, Lee D, Jacene H, Pryma D, Hope T, Saboury B, Capala J, Wahl RL. Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice. *J Nucl Med*. 2021 Dec;62(Suppl 3):60S-72S.
46. Hope TA, Calais J. PSMA PET in Prostate Cancer-A Biomarker or a Surrogate End Point?-Reply. *JAMA Oncol*. 2022 Feb 17.
47. Schöder H, Hope TA, Knopp M, Kelly WK, Michalski JM, Lerner SP, Tawab-Amiri A, Mann BS, Lin DW, Yu EY, Chen RC, Beach GC, Reeves SA; Members of the Working Group, Shankar LK. Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups. *J Clin Oncol*. 2022 Jan 11:JCO2102440.
48. Mailman J, Hope TA. Leadership in Patient Advocacy: A Conversation Between Josh Mailman and Thomas Hope. *J Nucl Med*. 2022 Apr;63(4):497-499.
49. Sgouros G, Dewaraja YK, Escorcía F, Graves SA, Hope TA, Iravani A, Pandit-Taskar N, Saboury B, St James S, Zanzonico PB. Reply LTE, Single time point tumour dosimetry assuming normal distribution of tumour kinetics. *J Nucl Med*. 2022 Mar 10:jnumed.121.263717.

50. Hope TA, Jadvar H. Updates to Appropriate Use Criteria for PSMA PET. J Nucl Med. 2022 May;63(5):14N.
51. Simon NI, Parker C, Hope TA, Paller CJ. Best Approaches and Updates for Prostate Cancer Biochemical Recurrence. Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-8.
52. Bukavina L, Luckenbaugh AN, Hofman MS, Hope T, Kamran SC, Murphy DG, Yamoah K, Ost P. Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer. Eur Urol. 2022 Nov 17:S0302-2838(22)02780-4. doi: 10.1016/j.eururo.2022.10.024.
53. Sabbagh A, Mohamad O, Lichter KE, Hope TA. Management of Patients with Recurrent and Metachronous Oligometastatic Prostate Cancer in the Era of PSMA PET. Cancers. 2022; 14(24):6194. <https://doi.org/10.3390/cancers14246194>
54. Garje R, Hope TA, Rumble RB, Parikh RA. Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Q and A. Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer Guideline Expert Panel. JCO Oncol Pract. 2023 Jan 24:OP2200753. doi: 10.1200/OP.22.00753.

BOOK CHAPTERS

1. Hope TA. "Hepatobiliary and Pancreatic Cancer PET/MRI." PET/MRI in Oncology: current and clinical applications. Eds. Iagaru A, Hope TA, Veit-Haibach P. Springer 2018.
2. Hope TA. "MRI Contrast Agents." PET/MRI in Oncology: current and clinical applications. Eds. Iagaru A, Hope TA, Veit-Haibach P. Springer 2018.
3. Hope MD, Ordovas KG, Meadows AK, Hope TA, Higgins CB, Reddy GP. "Magnetic Resonance Evaluation of Blood Flow." Imaging of the Cardiovascular System: Chpt. 17. Eds. Vincent Ho and Gautham Reddy. Elsevier 2010.
4. Burger IA and Hope TA. "Advances in Molecular Imaging 3 and Therapy and Its Impact in Oncologic Imaging." Diseases of the Abdomen and Pelvis 2023-2026, IDKD Springer Series: Chpt 3. Eds. J. Hodler et al. Springer 2023.

PUBLICATIONS – SCIENTIFIC ABSTRACTS

1. McGowan PO, Hope TA, Williams CL, Kelsoe G, Meck WH. Impairment of Social Recognition Memory in RAG1- but not RAG2-Deficient Mice. Program No. 778.7. 2002. Washington, DC: Society for Neuroscience, 2002.
2. Bammer R, Aksoy M, Lansberg MA, Hope T, Moseley ME, Herfkens RJ, Alley MT. Time-Resolved 3D Quantitative Flow MRI of the Major Intracranial Arteries. ISMRM, May 2004.
3. Wigström L, Hope T, Draney MT, Heiberg E, Bolger AF, Alley MT, Pelc NJ, Miller DC, Herfkens RJ. Segmentation and Characterization of Vortical Flow Patterns in MRI Phase-contrast Velocity Data. ISMRM, May 2005.
4. Hope TA, Nagle S, Alley MT, Bammer R. Time-Resolved 3D Quantitative Flow MRI of Intracranial Vessels: Comparative Evaluation at 1.5T and 3.0T in Combination with Parallel Imaging. RSNA, November 2006.
5. Hope TA, Miller DC, Alley MT, Markl M, Herfkens RJ. A Comparison of Flow Patterns in Ascending Aortic Aneurysms and Volunteers Using Four-Dimensional Magnetic Resonance Velocity Mapping. ISMRM-ESMRMB, May 2007.
6. Hope MD, Hope TA, Ordovas KG, Meadows A, Saloner D, Reddy GP, Alley MT, Higgins CB. Clinical

Evaluation of Aortic Coarctation with 4D Flow MR Imaging. ISMRM-ESMRMB, May 2008.

7. Hope TA, Hope MD, Bammer R, Alley MT. Combination of parallel imaging and cut-corner acquisition for neurovascular 4D-flow. ISMRM-ESMRMB, May 2008.
8. Hope TA, Herfkens RJ, Weil E. The Incidence of Nephrogenic Systemic Fibrosis in Patients with Renal Failure Who Have Received Gadopentetate Dimeglumine. ISMRM-ESMRMB, May 2008.
9. Hope TA, Chaopathomkul B, LeBoit PE, High WA, Rogut VS, Herfkens RJ, Brasch RC. Effect of Intravenous Iron on Nephrogenic Systemic Fibrosis in Rats. ISMRM, April 2009.
10. Hope MD, Hope TA, Meadows AK, Ordovas KG, Urbania TH, Alley MT, Higgins CB. Elevated Aortic Wall Shear Stress in Patients with Bicuspid Valves. ISMRM Cardiovascular Flow, Function and Tissue Mechanics, September 2009.
11. Hope TA, Hope MD, Alley MT, and Higgins CB. Analysis of Error in Mean Velocity, Individual Velocity Vectors, SNR and Wall Shear Stress Measurements in 4D Flow Acquisitions. ISMRM Cardiovascular Flow, Function and Tissue Mechanics, September 2009.
12. Hope TA, Chaopathomkul B, LeBoit PE, High WA, Rogut VS, Herfkens RJ, Brasch RC. Nephrogenic Systemic Fibrosis in Rats treated with Erythropoietin and Intravenous Iron. RSNA, November 2009.
13. Hope MD, Hope TA, Urbania TH, Ordovas KG, Alison AK, Alley MT, Higgins CB. Elevated Aortic Wall Shear Stress in a Subgroup of Patients with Bicuspid Valves. ISMRM, May 2010.
14. Hope TA, Hope MD, Miller DC, Markl M, Kvitting JE, Higgins CB, Herfkens RJ. Long Term Follow-Up of Patients Status Post Valve-Sparing Aortic Surgery with 4D-Flow. ISMRM, May 2010.
15. Hope TA, Brunwell AN, Wheeler SE, Brasch RC, Chapman H. The Effect of Omniscan on Hypoxia Inducible Factor-1 α (HIF-1 α) in Macrophages. MRA Club, October 2010.
16. Hope TA, Hope MD, Muzzarelli S, Ohliger M, Lu MT, Ordovas KG, Higgins CB. Clinical Evaluation of Cardiovascular Disease Using 4D Flow. RSNA, November 2010.
17. Hope TA, Crook SE, Hope MD. Flow acceleration and elevated wall shear stress with hypoplastic arch after aortic coarctation repair. ISMRM, May 2011.
18. Hope TA, Doherty A, Fu Y, Aslam R, Qayyum A, Brasch RC. Evaluation of gadolinium accumulation and fibrosis within the liver after the administration of gadoxetate in a rat model of cirrhosis. Contrast Media Research Group, October 2011.
19. Hope TA, LeBoit P, High W, Fu Y, Brasch RC. Evaluation of Imatinib Mesylate as a Possible Treatment for Nephrogenic Systemic Fibrosis in a Rat Model. ISMRM, May 2012.
20. Hope TA, Aslam A, Corvera CU, Monto A, Yee J, Yeh BM. Prospective Comparison of Gadoxetate MRI and Contrast Enhanced CT for the Diagnosis of Equivocal Lesions Seen on CT - Preliminary Results. ISMRM, May 2012.
21. Hope TA, Saranathan M, Hargreaves BA, Herfkens RJ, Vasanawala SS. Improvement of gadoxetate arterial phase capture with a high spatio-temporal resolution multiphase three-dimensional SPGR-dixon sequence. ISMRM, May 2013.
22. Hope TA, Stephens EH, Kari FA, Kvitting JPE, Miller DC, Herfkens RJ. Abnormal WSS and helical flow in Bicuspid Aortic Valve Patients Status Post Valve- Sparing Aortic Root Replacement. MRA Club, August 2013.
23. Hope TA, Aslam R, Weinstein S, Yeh BM, Yee J. The Utility Of Gadoxetate In The Evaluation Of HCC And Its Role In LI-RADS 2014. SAR, March 2014.

24. Sandeep A, Yeh BM, Aslam R, Weinstein S, Hope TA, Yee J. Abdominal incidentaloma recommendations: An interactive self-test module. ARRS, May 2014.
25. Hope TA, Aslam R, Yee J, Sesl A, Rapp J, Owens C, Saloner D. Initial Evaluation of the Utility of Ferumoxytol for MR Runoffs. ISMRM, May 2014.
26. Sandeep A, Yee J, Saloner D, Aslam R, Hope TA. Gadolinium enhanced MR imaging after therapeutic ferumoxytol dosage for iron-deficiency anemia – An in-vitro study for optimal contrast timing and dose determination. ISMRM, May 2014.
27. Ehman E, Umetsu SE, Fidelman N, Ferrell LD, Ohliger MA, Yeh BM, Yee J, Hope TA. Radiologic-pathologic correlation of post-treatment HCC: Ability of CT imaging features to predict residual or recurrent tumor. SCBT-MR, October 2014.
28. Arasu V, Gasper W, Downey R, Weinstein S, Aslam R, Hope T, Comparison of Gadolinium- versus Iron-based MRA Blood Pool Contrast Agents used in Assessment of Peripheral Vascular Disease. RSNA, December 2014.
29. Costa E, Shah A, Tanabe M, Heiken J, Fowler K, Hope T, Santillan C, Middleton M, Sirlin C, LI-RADS v2014: Interpretation and Categorization of MRI Findings Using Hepatobiliary Agents. RSNA, December 2014.
30. Kim S, Yeh B, Wu E, Wang Z, Hope T, Yee J, Zhao L, Chang W, Comparison of HCC Conspicuity on Delayed MR Images with Extracellular versus Hepatobiliary Contrast Agent for Patients with Compromised Liver Function. RSNA, December 2014.
31. Yeh M, Arasu V, Merry G, Hope T, Weinstein S, Aslam R, MRI Evaluation of the Female Pelvic Floor: Dynamic Imaging of Normal Function and Dysfunction. RSNA, December 2014.
32. Ehman E, Behr S, Aslam R, Yeh B, Ferrell L, Hope T, A Review of LI-RADS Categorization in 201 Pathology Proven Hepatocellular Carcinomas. RSNA, December 2014.
33. Behr S, Hope T, Nardo L, Ravanfar V, Verdin E, Savic D, Hawkins R, Seo Y. Ultrafast PET Acquisition Using Solid-state Photomultiplier-based PET Camera under a Strong Magnetic Field. RSNA, December 2014.
34. Ehman E, Umetsu S, Yeh B, Fidelman N, Ferrell L, Hope T. Liv-er Dye: A Radiology-Pathology Correlation of Treated and Recurrent Liver Lesions. RSNA, December 2014.
35. Hope TA, Pampaloni MH, Nakakura EK, VanBrocklin H, Slater J, Jivan S, Aparici CM, Yee J, Bergsland EK. Evaluation of DOTA-TOC PET/MRI combined with gadoxetate enhanced MRI for the evaluation of neuroendocrine tumors. Third Theranostics World Congress on Ga-68 and Radiopeptide Therapy, March 2015.
36. Hope TA, Aparici CM, Nakakura E, VanBrocklin H, Pampaloni MH, Slater J, Jivan S, Yee J, and Bergsland EK. Utility of combined Ga-68 DOTA-TOC PET and Eovist MRI utilizing PET/MRI. ISMRM, May 2015.
37. Hope TA, Verdin E, Behr S, Ohliger MA, Nakakura E, Corvera CU. Benefits of dedicated hepatic imaging using simultaneous PET/MRI. SNMMI, June 2015.
38. Pampaloni MH, Hope TA, Aparici CM, Nakakura E, VanBrocklin H, Slater J, and Bergsland EK. Quantitative ⁶⁸Ga-DOTATOC PET/CT in Patients with Metastatic or Recurrent Neuroendocrine Tumors. SNMMI, June 2015.
39. Hope MD, Hope TA, Zhu C, Faraji F, Haraldsson H, Saloner D. Ferumoxytol MRA as an Alternative to CTA for Common Chest Indications: TAVR and Pulmonary Embolism. Oral Presentation at MRA Club 2015, 27th Annual International Conference, Cincinnati.
40. Lehrman E, Weinstein S, Yee J, Gasper W, Hope T. Steady-state ferumoxytol enhanced magnetic resonance angiography of the lower extremities provides optimal characterization of vascular lesions for peripheral arterial disease patients with renal failure. Oral Presentation at MRA Club 2015, 27th Annual International Conference,

Cincinnati.

41. Zhu C, Hope TA, Haraldsson H, Faraji F, Saloner D, Hope MD. High resolution MRI for characterization of inflammation within abdominal aortic aneurysm. Oral Presentation at MRA Club 2015, 27th Annual International Conference, Cincinnati.
42. Flavell, RR, Bergsland E, Nakakura E, Pampaloni MH, Behr SC, Aparici CM, Yee J, Hope TA. A Primer on Interpreting Ga-68 DOTA-TOC PET/CT and How it Changes Patient Management. RSNA, December 2015.
43. Ehman E, Umetsu S, Fidelman N, Ferrell L, Ohliger MA, Yeh BM, Yee J, Hope TA. CT and MR Imaging Features to Predict Residual or Recurrent Hepatocellular Carcinoma after Trans-arterial or Percutaneous Treatment. RSNA, December 2015.
44. Monu NC, Fowler KJ, Heiken JP, Sirlin CB, Hussain HK, Kamadakone AR, Hope TA. Hepatobiliary Agent Technique: Maximizing Image Quality. RSNA, December 2015.
45. Santillan CS, Tang A, Fowler KJ, Heiken JP, Hope TA, Newton IG, Kagen AC, Bashir MR, Kambadakone AR, Mitchell DG, Shah A, Do RK, Kielar AZ, Sirlin CB. LI-RADS v2014 - Application and Future Directions. RSNA, December 2015.
46. Kluijfhout WP, Hope TA, Pasternak JD, de Keizer B, Vriens MR, Shen WT, Gosnell JE, Duh QY, Glastonbury CM, Pampaloni MH, Suh I. Preliminary Results of F18-Fluorocholine PET/MRI Shows Excellent Accuracy in Patients with Primary Hyperparathyroidism and Inconclusive Conventional Imaging. ECR, March 2016.
47. Chang ST, Loening AM, Vasanawala SS, Hope TA, Skin LK. Ferumoxytol- Enhanced Magnetic Resonance Imaging (Fe-MRI): A Case-based Tutorial for the Abdominal Radiologist. SAR, March 2016.
48. Nguyen VT, Zucker DJ, Weinstein S, Aslam R, Yeh B, Hope TA, Yee J. Evaluation of Extracolonic Findings on Low Dose CT Colonography. SAR, March 2016.
49. Hope TA. SAR 2014 Wylie J. Dodds Research Award: Simultaneous ⁶⁸Ga-DOTA-TOC PET/MRI with Gadoxetate Disodium in Patients with Neuroendocrine Tumors. SAR, March 2016.
50. Zhu C, Hope TA, Haraldsson H, Faraji F, Saloner D, Hope MD. High Resolution MRI for Characterization of Inflammation Within Abdominal Aortic Aneurysm. ISMRM, May 2016.
51. Leynes A, Yang J, Shanbhag D, Kaushik S, Wiesinger F, Seo Y, Hope TA, and Larson P. Quantitative Evaluation of the Effect of Bone on Pelvic Lesion Uptake for MR-Based Attenuation Correction on an Integrated Time-Of-Flight PET/MRI System. ISMRM, May 2016.
52. Jiang W, Ong F, Johnson K, Nagle S, Hope TA, Lustig M, Larson P. Soft-Gating and Motion Resolved Reconstructions for Free-Breathing Pulmonary Imaging. ISMRM, May 2016.
53. Wiesinger F, Kaushik S, Menini A, Ahn S, Cheng L, Cozzini C, Hope T, Yang J, Larson P, Shanbhag D. Whole Body Skeletal Imaging Using Zero TE. ISMRM, May 2016.
54. Wiesinger F, Kaushik S, Shanbhag D, Chebrolu V, Vaidya Vivek, Ahn S, Cheng L, Leynes A, Yang J, Hope T, Larson P, ZT-AC: Zero TE Based PET/MR Attenuation Correction. ISMRM, May 2016.
55. Tao D, Ravanfar V, Nakakura EK, Bergsland EK, Hope TA. Respiratory compensated PET with DOTA-TOC PET/MRI using motion registered and gated reconstruction. SNMMI, June 2016.
56. Laguna B, Bartlett D, Flavell R, Dillon W, Glastonbury C, Hope T. Incidence and location of metastatic disease in 369 patients with HNSCC using PET/CT: impact on PET/MRI protocol design. SNMMI, June 2016.
57. Nardo L, Facchetti L, Martin T, Wolf J, Hope T, Link TM, Pampaloni MH. Diagnostic Confidence of FDG PET Imaging in Patients with Multiple Myeloma assessed by PET/MRI, PET/CT and Whole Body MRI. SNMMI, June

2016.

58. Yang K, Weisinger F, Kaushik S, Shanbhag D, Leynes A, Hope T, Larson P, Vigneron D, Majumdar S, Seo Y. Quantitative evaluation of Zero TE MR-based attenuation correction (ZTAC) for PET/MRI brain imaging in an integrated time-of-flight PET/MRI device: comparison to CT-based AS (CTAC) and atlasCT-base AC (ATAC). SNMMI, June 2016.
59. Hope TA, Pampaloni MH, Nakakura EK, Van Loon K, Bergsland EK. Evaluation of uncinate process uptake on DOTA-TOC PET/MRI. NANETS, September 2016.
60. Hope TA, Nguyen HG, Greene KL, Westphalen AC, Cooperberg MR, Shinohara K, Carroll PR. ⁶⁸Ga-PSMA-11 in Intermediate to High-Risk Prostatectomy Patients. Prostate Cancer Foundation, October 2016.
61. Berniker AV, Kallianos KG, Henry TS, Ordovas KG, Hope TA, Hope MD. Ferumoxytol-Enhanced Thoracic MRA: Pictorial Review of Routine and Novel Clinical Applications. RSNA, November 2016.
62. Yee J, Santos C, Weinstein S, Candia S, Hope TA, Yeh BM, Jha P. Defining the Characteristics of Lipomas on CT Colonography. RSNA, November 2016.
63. Santillan CS, Newton IG, Mamidipalli A, Shah A, Hope TA, Heba ER, Valasek M, Tang A, Costa EA, Sirlin CB. Hepatocarcinogenesis, MRI, and LI-RADS-It's Not Always HCC! RSNA, November 2016.
64. Kim D, Chang AJ, Westphalen AC, Behr SC, Feng F, Carroll PR, Zagoria R, Hope TA. Sites of Recurrence after Radiation in Patients with Prostate Cancer Detected by Post-treatment ⁶⁸Ga-PSMA-11 PET. SAR, March 2017.
65. Hope TA, Nguyen H, Greene KJ, Westphalen AC, Cooperberg M, Shinohara K, Carroll PR. Evaluation of ⁶⁸Ga-PSMA-11 PET for Detection of Nodal Metastases in Intermediate to High-Risk Prostatectomy Patients. SAR, March 2017.
66. Lee JY, Santos C, Weinstein S, Ohliger MA, Monto A, Yee J, Hope TA. Evaluation of an Abbreviated Screening MRI Protocol for Patients at Risk for HCC. SAR, March 2017.
67. Yang J, Wiesinger F, Menini A, Liu H, Hope T, Seo Y, Larson P. Respiratory Phase-Matched MR-based Attenuation Correction (MRAC) for Four-Dimensional (4D) PET in PET/MRI: A Feasibility Study. ISMRM, May 2017.
68. Hicks R, Loening A, Vasanawala S, Ohliger M, Hope T. Variable Refocusing Flip Angle Single-Shot Fast Spin Echo Imaging of Liver Lesions: Improved Lesion Contrast and Speed. ISMRM, May 2017.
69. Leynes A, Yang J, Shanbhag D, Kaushik S, Wiesinger F, Seo Y, Hope T, Larson P. Direct Pseudo-CT Image Synthesis Using Deep Learning for Pelvis PET/MR Attenuation Correction. ISMRM, May 2017.
70. Huo E, Tian B, Saloner D, Hope M, Hess C, Dillon W, Hope T. Contrast Deposition Within the Dentate Nucleus After Repetitive Administration: Comparison of Linear versus Macrocyclic Gadolinium Contrast Agents. ISMRM, May 2017.
71. Gillian D, Hope T, Larson P. 3D Printed Phantom for PETMR Attenuation Correction. ISMRM, May 2017.
72. Lake S, Greene K, Westphalen A, Behr S, Zagoria R, Small E, Carroll P, Hope T. Optimal MRI sequences for ⁶⁸Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer. ISMRM, May 2017.
73. Kaushik S, Shanbhag D, Leynes A, Ravishankar H, Yang J, Larson P, Hope T, Wiesinger F. Deep Learning based pseudo-CT estimation using ZTE and Dixon MR images for PET attenuation correction. ISMRM, May 2017.
74. Wiesinger F, Ahn S, Kaushik S, Cozzini C, Beque D, Cheng L, Yang J, Leynes A, Shanbhag D, Hope T, Larson

P. Whole-Body, Zero TE Based Pseudo CT Conversion. ISMRM, May 2017.

75. Burke C, Hope T, Ohliger M, Wang Z, Van Loon K, Varma M. PET/MRI for rectal cancer staging: Longer PET acquisition times result in increased identification of nodal metastatic disease. ISMRM, May 2017.
76. Lawhn Heath CA, Flavell R, Deller T, Lake S, Carroll PR, Hope T. Scatter artifact with 68Ga PSMA-PET: severity reduced with furosemide diuresis and improved time-of-flight scatter correction. SNMMI, June 2017.
77. Hope T, Tosun D, Khalighi M, Yang J, Wynn M, Hess C, Rabinovici G, Kramer J, Larson P. Improvement in quantitative amyloid imaging using ZTE-based attenuation correction in PET/MRI. SNMMI, June 2017.
78. Hope TA, Aggarwal RR, Greene KL, Chee B, Tao D, Feng FY, Chang A, Cooperberg MR, Ryan CJ, Small EJ, Carroll PR. Effect of Ga-68 PSMA-11 PET on management in patients with recurrent prostate cancer. ASCO, 2017.
79. Chee B, Aggarwal RR, Tao D, Greene KL, Cooperberg MR, Feng FY, Chang A, Ryan CJ, Small EJ, Carroll PR, Hope TA. Effect of Ga-68 PSMA-11 PET on management in patients with recurrent prostate cancer. SNMMI, June 2017.
80. Hope TA, Fidelman N, Jivan S, Bergsland EK. Pilot Study: Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor. NANETS, October 2017.
81. Chan H, Moseley C, Van Loon K, Bergsland EK, Pampaloni MH, Hope TA. Correlation of DOTATOC uptake and pathologic grade in neuroendocrine tumors. NANETS, October 2017.
82. Hicks RM, Hope TA, Jivan S, Nakakura E, Fidelman N, Pampaloni MH, Bergsland E. Peptide Receptor Radionuclide Therapy: The Dawn of the Era of Theranostics. RSNA, December 2017.
83. Lawhn-Heath CA, Flavell RR, Aggarwal R, Feng FY, Ryan C, Small E, Carroll RP, Nguyen HG, Westphalen AC, Zagoria RJ, Pampaloni MH, Hope TA. Imaging with PSMA PET: What We've Been Missing. RSNA, December 2017.
84. Hope TA, Fidelman N, Jivan S, Bergsland EK. Y90 DOTATOC Intra-Arterial Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors. SNMMI Mid-Winter Meeting, January, 2018.
85. Gadzinski AJ, Greene KL, Carroll PR, Ryan CJ, Feng FY, Hope TA. Detecting prostate cancer lesions using Gallium-68 PSMA PET for biochemical recurrence following radical prostatectomy. ASCO GU, February, 2018.
86. Jordan EJ, Bailey JJ, Ohliger MA, Wang ZJ, Van Loon K, Varma MG, Hope TA. PET/MRI for Rectal Cancer Staging: Radiologic-Pathologic Correlation. SAR Annual Meeting, March, 2018.
87. Hicks RM, Westphalen AC, Simko JP, Greene KL, Nguyen HG, Zhang L, Carroll PR, Hope TA. Diagnostic Accuracy of 68Ga-PSMA-11 PET Compared with Multiparametric MRI for the Detection of Prostate Cancer in Patients Undergoing Radical Prostatectomy with Explant Histopathologic Correlation. SAR Annual Meeting, March, 2018.
88. Hope TA, Fidelman N, Jivan S, Bergsland EK. Y90 DOTATOC Intra-Arterial Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors. Neuroendocrine Tumor Research Foundation, April, 2018.
89. Fendler W, Calais J, Gartmann J, Nickols NG, Reiter RE, Rettig M, Hope TA, Slavik R, Gupta P, Quon A, Allen-Auerbach M, Herrmann K, Czernin J, Eiber M. Accuracy of 68Ga-PSMA11 PET/CT on recurrent prostate cancer: Preliminary results from a phase 2/3 prospective trial. ASCO, June 2018.
90. Kaushik S, Cozzini C, Bylund M, Yang J, Shanbhag D, Jonsson J, Lundman J, Hope T, Nyholm T, Leynes A, Larson P, Wiesinger F. Deep Learning based pseudo-CT computation and its application for PET/MR attenuation correction and MR-guided radiation therapy planning. ISMRM, June 2018.

91. Ahn S, Yang J, Liu J, Seo Y, Hope T, Larson P, Wiesinger F. Joint estimation applied to attenuation correction for quiescent period respiratory gated PET data in PET/MR. ISMRM, June 2018.
92. Larson P, Han M, Cao P, An H, Fowler K, Keenan K, Stupic K, Laforest R, Hope T. Quantitative Imaging for Development of PET/MRI phantoms. ISMRM, June 2018.
93. Fendler W, Herrmann K, Calais J, Hadaschik B, Giesel F, Hartenbach M, Hope T, Maurer T, Weber W, Matthias E. PROstate cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. SNMMI, June 2018.
94. Jun J, Pampaloni MH, Villanueva-Meyer J, Ravanfar V, Suh I, Hope T. 18-F-Fluorocholine PETMR: Optimizing Injection Delay for Parathyroid Adenoma Localization. SNMMI, June 2018.
95. Smith R, Tao D, Lawhn Heath C, Hope T. 68Ga-PSMA PET/MRI: Determining ideal acquisition times to reduce noise and increase image quality. SNMMI, June 2018.
96. Chandramohan D, Cao P, Han M, An H, Fowler K, Stupic K, Keenan K, Sunderland J, Kinahan P, Laforest R, Hope T, Larson P. Quantitative imaging of bone material analogues for PET/MRI phantoms. SNMMI, June 2018.
97. Fendler F, Calais J, Gartmann J, Nickols N, Reiter R, Rettig M, Hope T, Slavik R, Gupta P, Quon A, Allen-Auerbach M, Herrmann K, Czernin J, Eiber M. 68Ga-PSMA11 PET/CT localizes recurrent prostate cancer with high accuracy: preliminary results from a phase 2/3 prospective trial. SNMMI, June 2018.
98. Laforest R, Khalighi MM, Byrd D, Hongyu A, Larson P, Sunderland J, Kinahan P, Hope T. Harmonization of PET Image Reconstruction Parameters on Multiple PET/MRI System. SNMMI, June 2018.
99. Hope TA, Calais J, Dieckmann W, Millo C. Octreoscan vs DOTATATE PET: Comparison of Krenning Scoring. NANETS, September 2018.
100. Mulvey CK, Hooker C, Chan JA, Aggarwal RR, Cinar P, Hope T, Kolli K, Zhang L, Calabrese S, Grabowsky JA, Zhang J, Fong L, Raj NP, Bergsland EK. Pembrolizumab-based therapy in previously treated high grade extrapulmonary neuroendocrine carcinomas. NANETS, September 2018.
101. Chan H, Zhang L, Paciorek LA, Shih B, Nakakura E, Bergsland EK, Hope T, Van Loon K. Detection of Bone metastases in Neuroendocrine Tumors (NETs) with DOTA-TOC/TATE Imaging. NANETS, September 2018.
102. Mulvey CK, Bergsland EK, Lindsay S, Hope TA. Radiographic Predictors of Response to 177Lu-DOTATATE. NANETS, September 2018.
103. Mahuron M, Lin M, Shih B, Javeed Z, Kasai Y, Kim G, Hope T, Bergsland EK, Warren R, Nakakura E. A minimally invasive approach for the surgical management of neuroendocrine tumors of the ileum (i-NETs). NANETS, September 2018.
104. Xu MJ, Kornberg Z, Gadzinski AJ, Diao S, Cowan JE, Wu SY, Boreta L, Spratt DE, Nguyen HG, Cooperberg MR, Davicioni E, Roach M, Hope TA, Carroll PR, Feng FY. Genomic risk predicts for molecular imaging detected metastatic nodal disease in prostate cancer. ASTRO, October 2018.
105. Boreta L, Gadzinski AJ, Wu SY, Xu M, Nguyen HG, Roach M, Greene KL, Carroll PR, Feng FY, Hope TA. Location of prostate cancer recurrence detected by Gallium-68 PSMA PET in men eligible for salvage radiation. Society of Urogenital Oncology, November 2018.
106. Gadzinski AJ, Washington SL, Hope TA, Greene KL, Nguyen HG, Tao D, Smith R, Hicks RM, Flavell RR, Westphalen AC, Carroll PR. PSMA PET staging accuracy in intermediate and high-risk prostate cancer. Society of Urogenital Oncology, November 2018.

107. Fendler WP, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, Ilhan J, Small EJ, Smith MR, Maurer T, Herrmann K, Perez PM, Hope TA, Rauscher I, Londhe A, Lopez-Gitlitz A, Cheng A, Eiber M, Hadaschik B. PSMA-PET Results in a Nonmetastatic Castration-Resistant Prostate Cancer SPARTAN-Like Population That Is Negative by Conventional Imaging. Society of Urogenital Oncology, November 2018.
108. Zulfiqar M, Gagnon MH, Yoneda N, Sirlin CB, Hope TA, Hecht EM, Ronot M, Matsui O, Bastati N, Chernyak V, Ba-Ssalamah A, Bashir M. Hepatocellular Adenomas: Understanding the Pathomolecular Lexicon, Imaging Features, Terminology, and Pitfalls to Inform a Standardized Approach (LI-RADS Benign Lesion Algorithm). RSNA, November 2018.
109. Frencher, JT, Daud A, Behr SC, Pampaloni M, Flavell RR, Hope TA. PET/CT Imaging of Tumor Response and Immune-Related Side Effects of Checkpoint Inhibitor Therapy in Cutaneous Melanoma. RSNA, November 2018.
110. Fendler WP, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, Ilhan H, Saad F, Small EJ, Smith MR, Perez PM, Hope TA, Rauscher I, Londhe A, Lopez-Gitlitz A, Cheng S, Maurer T, Herrmann K, Eiber M, Hadaschik BA. PSMA-PET Results in a Nonmetastatic Castration-Resistant Prostate Cancer SPARTAN-Like Population That Is Negative by Conventional Imaging. SUO, November 2018.
111. Hadaschik BA, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, Ilhan H, Saad F, Small EJ, Smith MR, Perez PM, Hope TA, Rauscher I, Londhe A, Lopez-Gitlitz A, Cheng S, Maurer T, Herrmann K, Eiber M, Fendler WP. Prostate-specific membrane antigen positron-emission tomography (PSMA-PET) in high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC) SPARTAN-like patients (pts) negative by conventional imaging. AUA, May 2019.
112. Kim SJ, Dillon WP, Hope TA, El-Sayed IH, van Zante A, Wu K, Masharani U. Ectopic thyroid-stimulating hormone-secreting pituitary adenoma of the nasopharynx diagnosed by 68Ga-DOTA-TATE PET/CT. Endocrine Society, March 2019.
113. Hadaschik BA, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, Ilhan H, Saad F, Small EJ, Smith MR, Perez PM, Hope TA, Rauscher I, Londhe A, Lopez-Gitlitz A, Cheng S, Maurer T, Herrmann K, Eiber M, Fendler WP. Prostate-Specific Membrane Antigen Positron-Emission Tomography in High-Risk Nonmetastatic Castration-Resistant Prostate Cancer SPARTAN-like Patients Negative by Conventional Imaging. EAU, March 2019.
114. Hadaschik BA, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, Ilhan H, Saad F, Small EJ, Smith MR, Perez PM, Hope TA, Rauscher I, Londhe A, Lopez-Gitlitz A, Cheng S, Maurer T, Herrmann K, Eiber M, Fendler WP. Prostate-Specific Membrane Antigen Positron-Emission Tomography in High-Risk Nonmetastatic Castration-Resistant Prostate Cancer SPARTAN-like Patients Negative by Conventional Imaging. AUA, April 2019.
115. St. James S, Bergsland EK, Padilla-Morales E, Hope TA. Patient level dosimetry for peptide receptor radionuclide therapy: proof of concept for patients receiving 177Lu-DOTATATE. SNMMI Annual Meeting, June 2019.
116. Hamdi M, Chandramohan D, Larson P, Hope T and Laforest R. A lesion insertion tool to study the impact of attenuation correction strategy in PET/MRI. SNMMI Annual Meeting, June 2019.
117. Padilla-Morales E, Tan A, Bergsland EK, Hope TA. Comparison of Patient Experience with Commercial Versus Compounded Amino Acid Infusion for 177Lu-DOTATATE Therapy. SNMMI Annual Meeting, June 2019.
118. Graybiel C, Bergsland EK, Pampaloni MH, Hope TA. Value of PET/MRI in Distinguishing Physiologic Versus Malignant Uncinate Process Uptake on 68Ga-DOTATATE. SNMMI Annual Meeting, June 2019.
119. Mulvey CK, Raj NP, Chan JA, Aggarwal RR, Cinar P, Hope TA, Kolli K, Zhang L, Calabrese S, Grabowsky JA, Modaresi L, Kelly V, Stonely D, Munster PN, Reidy DL, Fong L, Bergsland EK. Pembrolizumab-based therapy in previously treated high grade extrapulmonary neuroendocrine carcinomas. ASCO, June 2019.

120. Lawhn Heath C, Fidelman N, Bergsland E, Hope T. Intra-Arterial Peptide Receptor Radionuclide Therapy Using Y-90 DOTATOC for Hepatic Metastases of Gastroenteropancreatic Neuroendocrine Tumors. NANETS Annual Meeting, October 2019.
121. Kasai Y, Mahuron K, Hirose K, Corvera C, Kim G, Hope T, Shih B, Warren R, Bergsland E, Nakakura E, Prognostic Impact of a Large Mesenteric Mass > 2 Cm in Ileal Neuroendocrine Tumors. NANETS Annual Meeting, October 2019.
122. Lawhn-Heath CA, Pampaloni MH, Fidelman N, Aggarwal R, Bergsland E, Hope TA. Peptide Receptor Radionuclide Therapy (PRRT): 2019 Update. RSNA, December 2019.
123. Fendler W, Ferdinandus J, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig M, Gartmann J, Smith R, Small EJ, Slavik R, Carroll P, Herrmann K, Czernin J, Hope T. Impact of 68Ga-PSMA-11 PET on the management of biochemically recurrent prostate cancer in a prospective single-arm clinical trial. GU ASCO 2020, February 2020.
124. Chu C, Alshalalfa M, Sjostrom M, Zhao S, Herlemann A, Chou J, Mahal MA, Kishan AU, Spratt DE, Karnes J, Small EJ, Wong AC, Porten SP, Hope T, Davicioni E, Nguyen PL, Carroll P, Schaeffer EM, Feng FY, Cooperberg MR. Characterization of PSMA and 18F-fluciclovine transporter gene expression in localized prostate cancer. GU ASCO 2020, February 2020.
125. Borno H, Lin TK, Odisho AY, Desai A, Koshkin VS, Werner K, Legaspi N, Bell A, Hope T. Disparities in receipt of molecular imaging in biochemical recurrent prostate cancer. GU ASCO 2020, February 2020.
126. Chu C, Alshalalfa M, Sjostrom M, Zhao S, Herlemann A, Jonathan Chou J, Mahal B, Kishan A, Spratt D, Cooperberg M, Karnes J, Small S, Nguyen P, Wong A, Hope T, Sima Porten S, Davicioni E, Carroll PR, Schaeffer E, Feng F. Characterization of PSMA and 18F-Fluciclovine Transporter Gene Expression In Localized Prostate Cancer. AUA, May 2020.
127. Hope TA, Armstrong W, Murthy V, Juarez R, Lawhn Heath C, Behr S, Barbato F, Ceci F, Farolfi A, Schwarzenboeck S, Unterrainer M, Zacho H, Nguyen H, Cooperberg M, Carroll P, Reiter R, Holden S, Fendler W, Zhu S, Eiber M, Herrmann K, Czernin J, Calais J. Accuracy of 68Ga-PSMA-11 for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Study. AUA, May 2020.
128. Huang FW, Trinh B, Wang S, Hope TA. Combined 18F-NaA and fluciclovine administration for PET imaging of prostate cancer. ASCO, May 2020.
129. Hope TA, Armstrong W, Murthy V, Lawhn Heath C, Behr S, Barbato F, Ceci F, Farolfi A, Schwarzenboeck S, Unterrainer M, Zacho H, Nguyen H, Cooperberg M, Carroll P, Reiter R, Holden S, Fendler W, Zhu S, Eiber M, Czernin J, Calais J. Accuracy of 68Ga-PSMA-11 for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: A multicenter prospective phase III imaging study. ASCO, May 2020.
130. Ferdinandus J, Fendler W, Czernin J, Eiber M, Flavell R, Behr S, Katherine W, Lawhn-Heath C, Pampaloni M, Reiter R, Rettig M, Gartmann J, Murthy V, Slavik R, Carroll P, Herrmann K, Calais J, Hope T. Impact of 68Ga-PSMA-11 PET on the Management of recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial. SNMMI Annual Meeting, July 2020.
131. Hamdi M, Ying C, An H, Hope T, Laforest R. Evaluation of different attenuation approaches in PET/MRI on quantification in the brain using a lesion simulator. SNMMI Annual Meeting, July 2020.
132. Tranel J, St. James S, Feng FY, Hope TA. Microdistribution of absorbed dose from alpha and beta emitters contained within the blood pool in a bone marrow model. AAPM/COMP Annual Meeting, July 2020.
133. Trinh B, Cooperberg M, Federspiel M, Huang F, Lawhn Heath C, Wang S, Hope T. Combined 18F-NaF and Fluciclovine Administration for PET Imaging of Prostate Cancer. SNMMI Annual Meeting, July 2020.

134. Chiu L, Lawhn-Heath C, Behr S, Juarez R, Perez P, Lobach I, Bucknor M, Hope T, Flavell R. Factors predicting metastatic disease in 68Ga-PSMA-11 PET positive osseous lesions in prostate cancer. SNMMI Annual Meeting, July 2020.
135. Kasai Y, Mahuro K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK. A novel stratification of mesenteric mass involvement as a predictor of challenging mesenteric lymph node dissection by minimally invasive approach for ileal neuroendocrine tumors. NANETS Annual Meeting, October 2020.
136. Kasai Y, Hirose K, Corvera CU, Kim GE, Hope TA, Warren RS, Bergsland EK, Nakakura EK. Upfront Interventional Treatments Prior to Liver-Progression for Small Bowel Neuroendocrine Liver Metastasis. NANETS Annual Meeting, October 2020.
137. Johnson GB, Drzezga A, Woodard PK, Hope TA, Nadel HR, El Fakhri G. PET/MRI Update 2020. RSNA Annual Meeting, December 2020.
138. Hope TA, Armstrong W, Juarez R, Murthy V, Lawhn Heath C, Behr S, Barbato F, Ceci F, Farolfi A, Schwarzenboeck S, Unterrainer M, Zacho H, Nguyen H, Cooperberg M, Carroll P, Reiter R, Holden S, Fendler W, Zhu S, Eiber M, Czernin J, Calais J. Accuracy of 68Ga-PSMA-11 for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: A multicenter prospective phase III imaging study. RSNA Annual Meeting, December 2020.
139. Li Y, Lawhn-Heath C, Hope TA. Current Status and Future Prospects in Radioligand Therapy (RLT). RSNA Annual Meeting, December 2020.
140. Calais J, Armstrong WR, Kishan AU, Booker KM, Hope TA, Czernin J, Nickols NG. Impact of PSMA PET/CT on SRT Planning: Preliminary Results From The Randomized Phase 3 Trial NCT03582774. ASCO GU, February 2021.
141. Aggarwal RR, Sam SL, Koshkin VS, Small EJ, Feng FY, Kouchkovsky I, Kwon DH, Friedlander TW, Borno H, Bose R, Chou J, Desai A, Rodvelt TJ, Aslam M, Rastogi M, Fong L, Hope TA. Immunogenic priming with 177Lu-PSMA-617 plus pembrolizumab in metastatic castration resistant prostate cancer (mCRPC): A phase 1b study. ASCO Annual Meeting, June 2021.
142. Chan JA, Raj NP, Aggarwal RR, Calabrese A, DeMore A, Dhawan MS, Fattah D, Fong L, Grabowsky J, Hope TA, Kolli KP, Munster PN, Perez K, Reidy DL, Von Fedak S, Zhang L, Bergsland EK. Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: Results of Part B (pembrolizumab + chemotherapy). ASCO Annual Meeting, June 2021.
143. Hope TA, Graves C, Calais J, Ehman EC, Johnson GB, Thompson D, Duh QY, Seib C, Maya A, Gosnell J, Wen S, Roman S, Sosa JA, Kluijfhout W, Villanueva-Meyer J, Pampaloni M, Suh I. Accuracy of 18F-fluorocholine PET for the detection of parathyroid adenomas: prospective single center study. SNMMI Annual Meeting, 2021.
144. Lin DS, De Kouchkovsky I, Aggarwal R, Hope T. The increased prevalence of low and heterogeneous PSMA uptake in the setting of metastatic castration-resistant prostate cancer. SNMMI Annual Meeting, 2021.
145. Tranel J, Feng FY, Hope TA, St. James ST. Impact of cellularity and heterogeneity on deposited absorbed dose patterns of alpha and beta emitters in a model of tumoral clusters. SNMMI Annual Meeting, June 2021.
146. Tranel J, Feng FY, Hope TA, St. James S. Impact of cellularity and heterogeneity on deposited absorbed dose patterns of alpha and beta emitters in a model of tumoral clusters. European Congress of Medical Physics (ECMP) Meeting, June 2021
147. Koh E, Cho CH, I Suh I, Hope TA, Agarwal SK, Duh QY, Shoback D. Localizing Parathyromatosis via ¹⁸Fluorocholine-PET and MRI in a Patient with an Activating GCM2 Mutation and Familial Isolated Hyperparathyroidism. ASBMR Annual Meeting, 2021.

148. Hope TA, Aggarwal RR, Dhawan MS, Kelley RK, Flavell RR, Lawhn Heath C, Li Y, Porten SP, Rugo HS, Yom SS, Ippisch R, Koshkin SV. Imaging of Solid Tumors Using 68Ga-FAP-2286. ASCO Annual Meeting, 2022.
149. Djaïleb L, Armstrong WR, Thompson D, Gafita A, Farolfi A, Rajagopal A, Juarez R, Cooperberg M, Carroll P, Washington S, Czernin J, Reiter RE, Hope TA, Calais J. Predictive value of extra-prostatic disease Detection by pre-operative PSMA-PET for biochemical recurrence free survival in patients treated with Radical Prostatectomy and Pelvic Lymph Node Dissection: follow-up analysis of a Multicenter Prospective Phase 3 Imaging Trial. ASCO Annual Meeting, 2022.
150. Armstrong WR, Kishan AU, Booker K, Fendler WP, Hope T, Nichols N, Czernin J, Calais J. Impact of PSMA PET/CT on prostate cancer salvage radiotherapy management: Results from the prospective randomized phase 3 trial [PSMA SRT NCT03582774]. ASCO Annual Meeting, 2022.
151. Hotta H, Gafita A, Murthy V, Benz MR, Sonni I, Burger I, Eiber M, Emmett L, Farolfi A, Fendler WP, Hofman MS, Hope TA, Kratochwil C, Czernin J, Calais J. PSMA PET tumor-to-salivary glands ratio (PSG score) to predict response to Lu-177 PSMA radioligand therapy: An international multicenter retrospective study. ASCO Annual Meeting, 2022.
152. Kline B, Hope TA. First-in-human evaluation of 68Ga-FAP-2286, a fibroblast activation protein targeted radionuclide." SNMMI Annual Meeting, 2022.
153. Hotta H, Gafita A, Murthy V, Benz MR, Sonni I, Burger I, Eiber M, Emmett L, Farolfi A, Fendler WP, Hofman MS, Hope TA, Kratochwil C, Czernin J, Calais J. PSMA PET tumor-to-salivary glands ratio (PSG score) to predict response to Lu-177 PSMA radioligand therapy: An international multicenter retrospective study. SNMMI Annual Meeting, 2022.
154. Tranel J, Feng FY, Hope TA. Impact of targeted sources on deposited absorbed dose of ^{177}Lu and ^{225}Ac in a model of cancer associated fibroblasts. SNMMI Annual Meeting, June 2022.
155. Tranel J, Palm S, Graves SA, Feng FY, Hope TA. Impact of targeted sources on deposited absorbed dose of ^{177}Lu and ^{225}Ac in a model of cancer associated fibroblasts. Swedish Radiation Research Association for young Scientists (SWE-RAYS) Workshop, July 2022.
156. Tranel J, Palm S, Graves SA, Feng FY, Hope TA. Impact of targeted sources on deposited absorbed dose of ^{177}Lu and ^{225}Ac in a model of cancer associated fibroblasts. Swedish academic initiative for radiation sciences and nuclear technology (SAINT) Workshop, July 2022.
157. Tranel J, Palm S, Graves SA, Feng FY, Hope TA. Deposited energy microdistribution of ^{177}Lu and ^{225}Ac in a model of cancer associated fibroblasts. New Modalities in Cancer Imaging and Therapy Workshop, October 2022.
158. Tranel J, Palm S, Graves SA, Feng FY, Hope TA. Absorbed dose microdistribution of ^{177}Lu and ^{225}Ac in a model of cancer associated fibroblasts. EANM Annual Meeting, October 2022.
159. Escobar D, Koshkin VS, Kline B, Chou J, Meng M, Friedlander T, Hope TA, Porten S. The Use of 68Ga-FAP-2286 PET Imaging in Patients with Localized Bladder Cancer. SUO 2022.
160. Fendler WP, Hope TA, Jiang F, Thompson D, Juarez R, Hernandez Pampaloni M, Auerbach MS, Gupta P, Benz MR, Calais J, Barbato F. Do bone scans over-stage disease compared to PSMA PET? An international multicenter retrospective study with blinded independent readers. ASCO Annual Meeting, June 2023.
161. Unterrainer L, Andrea Farolfi, Rosar F, Denis CS, Emmett L, de Kouchkovsky I, Hope TA, Hotta A, Gafita A, Djaïleb L, Czernin J, Calais J. Early changes of PSMA PET signal after initiation of androgen receptor signaling inhibitors in mCRPC: An international multicenter retrospective study. ASCO Annual Meeting, June 2023.

162. Djaileb L, Armstrong WR, Thompson D, Gafita A, Farolfi A, Grogan T, Cooperberg MR, Carroll P, Washington SL, Reiter RE, Eiber M, Herrmann K, Fendler WP, Czernin J, Hope TA, Calais J. Pre-surgical 68Ga-PSMA-11 PET for biochemical recurrence risk assessment: A surrogate of pelvic lymph node dissection? Follow-up analysis of a multicenter prospective phase 3 imaging trial. ASCO Annual Meeting, June 2023.
163. Morris M, Ulaner GA, Halperin DM, Strosberg JR, Mehr SH, Li D, Soares HP, Anthony LB, Kotiah SD, Jacene H, Pavel ME, Kunz PL, Ferreira DV, Li J, Ma K, Rearden J, Susan Moran, Hope TA, Singh S. ACTION-1 phase Ib/3 trial of RYZ101 in somatostatin receptor subtype 2-expressing (SSTR2+) gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Initial safety analysis. ASCO Annual Meeting, June 2023.
164. Maldonado E, Hope TA, Aggarwal RR, Kwon DH, Zhang L, Gordon K, Tong B, Bailey A, Kumar V, de Kouchkovsky I, Koshkin VS, Borno H, Chou J, Bose R, Fong L, Desai A, Friedlander TW, Small EJ. Defining the prevalence of inherited DNA damage repair genetic variants (DDRV) in men with prostate cancer (PCa) detected by PSMA PET. ASCO Annual Meeting, June 2023.
165. Hadaschik BA, Eiber M, Weber M, Kumar AR, Calais J, Czernin J, Ilhan H, Saad F, Kretschmer A, Brookman-May SD, Mundle S, Small EJ, Smith MR, Rivera PMP, Hope TA, Herrmann K, Hofman MS, Fendler WP. Prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) disease extent and overall survival (OS) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC): An international multicenter retrospective study. ASCO Annual Meeting, June 2023.
166. Carretero-González A, Kwon D, Shakhnazaryan N, Hong JC, Mohamad O, Feng MU, de Kouchkovsky I, Borno H, Bose R, Chou J, Desai A, Fong L, Friedlander TW, Koshkin VS, Feng FY, Aggarwal RR, Hope TA, Small EJ. Sequential metastasis-directed therapy (MDT) for oligometastatic prostate cancer (Oligo PCa) assessed by PET-based imaging. ASCO Annual Meeting, June 2023.
167. Behr SC, Wang Y, Houshmand S, Hong C, Hope TA. Added Value of Whole Body DWI MRI to patients undergoing PSMA PET. SNMMI Annual Meeting, June 2023.
168. Calais J, Benz MR, Jiang F, Thompson D, Juarez R, Hernandez Pampaloni M, Armstrong M, Barbato F, Gupta P, Auerbach MS, Fendler WP, Hope TA. Do Bone Scans Over Stage Disease Compared to PSMA PET? An international multicenter retrospective study with blinded independent readers. SNMMI Annual Meeting, June 2023.
169. Sarasa K, Tuchayi AM, Morley A, Saelee R, Juarez R, Lawhn Heath C, Wang Y, Hope TA. Comparison of 18F-DCFPyL and 68Ga-PSMA-11 for 177Lu-PSMA-617 Therapy Patient Selection. SNMMI Annual Meeting, June 2023.
170. Mar D, Lowery B, Diwanji D, Zhang L, Hope TA, Behr S, Flavell R. Detection of incidental malignancy on PSMA PET/CT imaging: a review of 2,054 sequential studies at an academic medical center. SNMMI Annual Meeting, June 2023.
171. Tuchayi AM, Kim S, Morley A, Saelee R, Wang Y, Lawhn Heath C, Juarez R, Hope TA. Initial Experience with 177Lu-PSMA-617 Therapy: Toxicity and Outcomes Post-Approval. SNMMI Annual Meeting, June 2023.
172. Le BK, Paciorek A, Moon F, Hope T, Mulvey C, Lindsay S, Nakakura E, Joseph N, Bergsland EK. Comparison of Well-differentiated Gastroenteropancreatic Grade 3 Neuroendocrine Tumors (G3NETs): De Novo and In The Setting of Apparent Grade Progression Over Time. NANETS Annual Meeting, October 2023.
173. Yadav S, Lawhn-Heath C, Lindsay S, Mirro R, Bergsland EK, Hope TA. The Impact of Post-Treatment Imaging in Peptide Receptor Radionuclide Therapy. NANETS Annual Meeting, October 2023.
174. Fidelman N, Keenan BP, Oh DY, Fong L, Chan K, Zhang L, Bergsland EK, Hope TA. A Pilot Study of Pembrolizumab and Peptide Receptor Radionuclide Therapy for Patients with Metastatic Well-Differentiated Neuroendocrine Tumors. NANETS Annual Meeting, October 2023.

175. Remick I, Hope TA, Ohliger M, Hong CW, Yang Y, Bergsland E, Lawhn Heath C, Su P, Itriago-Leon P. Initial Experience Using 0.55T MRI for Detection of Liver Metastases in NET Patients. NANETS Annual Meeting, October 2023.
176. Hope TA, Halperin D, Strosberg J, Jacene H, Tesselaar MET, Kunz PL, Ferreira D, Li J, Ma K, Rearden J, Moran S, Singh S. ACTION-1: A randomized Phase Ib/3 trial of RYZ101 compared with SoC in SSTR+ well-differentiated GEP-NET with progression following Lu-177 SSA

5 SIGNIFICANT PUBLICATIONS

1. **Hope TA**, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, Behr SC, Zhang L, Barbato F, Ceci F, Farolfi A, Schwarzenböck SM, Unterrainer M, Zacho HD, Nguyen HG, Cooperberg MR, Carroll PR, Reiter RE, Holden S, Herrmann K, Zhu S, Fendler WP, Czernin J, Calais J. Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial. *JAMA Oncol.* 2021 Sep 16.
2. Aggarwal R, Starzinski S, de Kouchkovsky I, Koshkin V, Bose R, Chou J, Desai A, Kwon D, Kaushal S, Trihy L, Rastogi M, Ippisch R, Aslam M, Friedlander T, Feng F, Oh D, Cheung A, Small E, Evans M, Fong L, **Hope TA**. Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. *Lancet Oncol.* 2023 Nov;24(11):1266-1276. doi: 10.1016/S1470-2045(23)00451-5. PMID: 37922930.
3. Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, **Hope TA**. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. *JAMA Oncol.* 2019 Mar 28.
4. Hicks RM, Simko JP, Westphalen AC, Nguyen HG, Greene KL, Zhang L, Carroll PR, **Hope TA**. Diagnostic Accuracy of 68Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer. *Radiology.* 2018 Sep 18;180788.
5. **Hope TA**, Truillet CC, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, Carroll PR, Small EJ, Evans MJ. Imaging Response to Androgen Receptor Inhibition Using 68Ga-PSMA-11 PET: First Human Experience. *J Nucl Med.* 2016 Sep 22.